



Exposure to Phthalate Mixtures and Inner-City Pediatric 
Allergic Disease and Airway Inflammation 









Submitted in partial fulfillment of the 
requirements for the degree 
of Doctor of Philosophy 
Under the Executive Committee 






















Allan Carpenter Just 
All Rights Reserved
Abstract 
Exposure to Phthalate Mixtures and Inner-City 
Pediatric Allergic Disease and Airway Inflammation 
Allan Carpenter Just 
Phthalate plasticizers are found in consumer products and home furnishing materials. 
Phthalate urinary metabolites are detected in nearly every sample in population-based studies 
indicating widespread exposure. Prior epidemiologic studies have associated vinyl flooring, a 
proxy for phthalate exposure, or house dust concentrations of phthalates with eczema and asthma 
in children. However, these studies lack adequate exposure measurements, consideration of the 
early life period, and prospective designs. In light of these gaps in the literature, we designed 
epidemiologic analyses to address our overarching hypothesis that early life exposure to a mixture 
of phthalates will have associations with adverse allergic and respiratory health outcomes in 
children. We tested this hypothesis in five self-contained manuscripts that characterize sources of 
exposure to phthalates in early life, demonstrate the application of new statistical methods for 
estimating effects of these highly correlated biomarkers, and test the association between early life 
exposure to phthalates and eczema and airway inflammation in children. 
Participants were enrolled from the longitudinal birth cohort of the Columbia Center for 
Children’s Environmental Health (CCCEH) in New York City. Phthalate metabolites were 
measured in prenatal and child urine samples at the Centers for Disease Control and Prevention. 
Questionnaires and visual inspections were combined with phthalate measurements from personal 
and indoor air sampling and urinary metabolite concentrations to examine sources and patterns of 
phthalate exposure associated with personal care product use and flooring materials in the home.  
The use of perfume and personal care products was associated with higher exposure to the 
metabolite of diethyl phthalate (DEP) but not di-n-butyl phthalate (DnBP). Vinyl flooring in the 
home was associated with higher indoor air and urinary metabolite concentrations for butylbenzyl 
phthalate (BBzP) but not di(2-ethylhexyl) phthalate (DEHP).  
Because some phthalates share exposure sources and have multiple metabolites, the urinary 
biomarker concentrations can be highly correlated. Using a reanalysis of the association between 
prenatal phthalate metabolites and reduced gestational age, we demonstrate that simple Bayesian 
models can estimate effects for highly correlated exposure measures without the instability of 
conventional modeling approaches.  
We found that prenatal concentrations of the metabolite of butylbenzyl phthalate were 
associated with the report of early-eczema but not atopy among children in the cohort. In a cross-
sectional analysis, children’s urinary concentrations of metabolites of diethyl phthalate and 
butylbenzyl phthalate were both associated with higher fractional exhaled nitric oxide, a marker of 
airway inflammation.  
These findings suggest several important sources of exposure to phthalates and demonstrate 
new methods for highly correlated exposures that have not been widely applied in the 
environmental health sciences. The association of biomarkers of exposure to butylbenzyl phthalate 
and eczema extend the findings of previous studies. Our results include the first report of an 
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This dissertation consists of a statement of hypotheses and specific aims, a background, 
five self-contained studies, a brief conclusion, and next steps. Each of the self-contained studies is 
organized as a scientific manuscript with its own abstract, introduction, methods, results, 
discussion, and references. As all scientific studies of this type are collaborative, the coauthors for 
each of these studies are named at the beginning of the respective chapters. 
The hypotheses and specific aims are the overarching questions that motivated this 
research. Each aim is addressed in one or more of the five self-contained studies. Specifically, the 
first two studies (Chapters 3 and 4) address the first specific aim of the dissertation: to identify 
sources and contributions to phthalate exposure in populations of concern, namely pregnant 
women and their children. These studies use biomarker and environmental exposure measurements 
along with data collected through surveys to study personal care products as potential sources of 
diethyl phthalate (DEP) and di-n-butyl phthalate (DnBP) during pregnancy and vinyl flooring in 
the residential environment as a potential source of butylbenzyl phthalate (BBzP) and di(2-
ethylhexyl) phthalate (DEHP) during childhood. 
The third study (Chapter 5) addresses the second specific aim of the dissertation: to develop 
a statistical approach for estimating associations between multiple correlated biomarkers and a 
health outcome measured on a continuous scale. The manuscript compares two commonly used 
statistical methods for highly correlated biomarkers with two simple Bayesian models. Because 
these methods have not yet been widely applied in the epidemiologic literature, and have not 
previously used biomarkers as continuous exposure estimates nor assessed the relationship to a 
continuous outcome measure, our study began with a reanalysis of an already published 




deemed an appropriate starting point to compare modeling approaches, as it had already been 
thoroughly analyzed with conventional statistical approaches including a careful consideration of 
potential confounders. Furthermore, this reanalysis particularly involved associations with the 
DEHP metabolites which are the most highly correlated subset of the phthalate metabolites. As an 
appendix to this study we include code utilizing free software tools so that others could potentially 
apply these methods in other situations with multiple correlated exposures. 
The fourth and fifth studies (Chapters 6 and 7) address the third specific aim: to examine 
associations between prenatal and children’s exposure to phthalates and health outcomes. The 
fourth study focuses on the association between prenatal exposure to BBzP and allergy related 
outcomes in children. The hypothesis is based on results from prior research associating house dust 
concentrations of BBzP with child eczema. The fifth study examines the association of children’s 
urinary metabolite concentrations for all four of the primary phthalates of interest (DEP, DnBP, 
BBzP and DEHP) and their association with concurrent fractional exhaled nitric oxide (FeNO), a 
marker of airway inflammation. 
 The background section of the dissertation provides a brief introduction to the topic areas 
and describes the connection between the five studies, their aims and approaches. However, 
detailed background specific to each of the self-contained studies is provided in the manuscripts 
themselves. Similarly, the methods sections are provided in the manuscripts. Finally, the overall 
conclusion seeks to summarize how these five studies address the specific aims of this dissertation, 
as well as discuss the relevance of the major findings and future directions for research in these 






Chapter 1: Statement of hypotheses 
This dissertation is an epidemiologic investigation of the sources of exposure to phthalates 
during pregnancy and early childhood, methods for statistical analysis of correlated biomarkers of 
phthalate exposures, and associations between exposures to phthalates and allergic and respiratory 
health outcomes in children. Phthalates are plasticizers commonly used in household and consumer 
products to confer flexibility. They are also used as solvents and fixatives in fragrances and 
personal care products. Widespread use has resulted in ubiquitous exposure to multiple phthalates. 
Recent epidemiologic studies show cross-sectional associations between several phthalates in 
house dust and childhood asthma and allergic diseases. However, patterns of prenatal and 
childhood exposure to phthalates are not well understood and population-based studies that use 
biomarkers of exposure are needed to establish whether or not phthalate exposure during 
pregnancy and early-life plays a role in pediatric allergic and respiratory disease.  
This epidemiologic study, conducted within an ongoing longitudinal birth cohort, fills these 
important research gaps. The research has four critical components: 1) the measurement of 
established biologic and environmental dosimeters of exposure to phthalates during pregnancy and 
early childhood; 2) the exploration of statistical methods for modeling effects of multiple 
correlated exposures; 3) the use of validated child outcome measures including proallergic 
immunoglobulin E (IgE) production, and fractional exhaled nitric oxide (FeNO) as a measure of 
airway inflammation; and 4) the use of a prospective birth cohort design to evaluate the impact of 
prenatal and early-life phthalate exposures on later childhood immunologic and respiratory 
outcomes. The following four phthalates will be evaluated: diethyl phthalate (DEP), di-n-butyl 
phthalate (DnBP), butylbenzyl phthalate (BBzP), and di(2-ethylhexyl) phthalate (DEHP). This 




phthalates will have associations with adverse allergic and respiratory health outcomes in 
children. We operationalized this hypothesis in three parts that dealt with exposure, statistical 
methods, and associations with health outcomes: 
 
Hypothesis 1: 
We predict that the use of personal care products and flooring materials in the home 
environment contribute to patterns of prenatal and childhood phthalate exposure. Specifically, we 
hypothesize that the use of perfume and other personal care products is associated with higher 
exposure to DEP and DnBP and that the presence of vinyl flooring materials that may contain 
phthalates is associated with higher exposure to BBzP but not DEHP. 
Specific Aim 1: sources of prenatal and childhood exposure 
We will characterize patterns of prenatal and early childhood exposure to phthalates in an 
urban cohort using questionnaire data on maternal use of personal care products and a checklist of 
materials in the home and examine associations with concentrations of phthalates measured in 




We hypothesize that simple Bayesian regression models can estimate associations between 
multiple correlated phthalate biomarker measures and a continuous health outcome and that these 
estimates will better reflect actual mixtures and be more stable than estimates from single 
biomarker or full linear regression models.  




We will construct simple Bayesian regression models to reanalyze an association of 
prenatal urinary metabolites with reduced gestational age and compare methods utilizing overall or 
grouped shrinkage with models fit for single metabolites and a full linear regression model with 
many correlated phthalates as predictors.  
 
Hypothesis 3: 
We predict that higher prenatal exposure to butylbenzyl phthalate will increase risk of early 
childhood eczema and production of proallergic immunoglobulin E (IgE) antibodies by age 5. We 
also predict that exposure to the four phthalates will be associated with increased concurrent 
airway inflammation (FeNO) among cohort children. 
Specific Aim 3a: eczema and atopy. 
We will develop multivariable linear regression models to examine the association between 
prenatal urinary concentrations of mono-benzyl phthalate (MBzP) and questionnaire based 
maternal report of children’s eczema as well as total serum IgE and allergen specific IgE measured 
at ages 2, 3, and 5 years. 
Specific Aim 3b: airway inflammation 
We will use regression models to examine the cross-sectional association of urinary 
phthalate metabolite concentrations with airway inflammation (FeNO) between ages 5-9.5. In 
addition, we will assess whether there is effect modification that varies these associations among 





Chapter 2: Background 
Sources of phthalates 
Phthalates are the diesters of 1,2-benzenedicarboxylic acid (phthalic acid) and are semi-
volatile organic compounds. They are commonly used plasticizers added to polymer based 
materials and consumer products, including up to 40% of polyvinyl chloride plastics, to confer 
flexibility or durability (NTP-CERHR 2006). They are also used as solvents and fixatives in 
fragrances and personal care products (Api 2001; ATSDR 1995; Cosmetic Ingredient Review 
Expert Panel 2005; Hubinger and Havery 2006). Phthalates are found in vinyl flooring, adhesives, 
pharmaceutical coatings, medical devices, personal care products, children’s toys, and as food 
contaminants among many other sources (Chou and Wright 2006; Schettler 2006). Although they 
are often referred to as a collective group, there are many phthalates in widespread commercial use 
with different predominant uses, physical and chemical characteristics, and toxicologic profiles for 
each. The four phthalates (DEP, DnBP, BBzP, DEHP) that are the main focus of this study are of 
particular interest based on previous epidemiologic and toxicologic studies discussed below. The 









Figure 1: Chemical structures of four phthalates of interest 
 
Exposure and measurement 
These four phthalates of interest are high production volume chemicals. Population based 
studies, including nationally representative studies in the United States (NHANES), found 
evidence of nearly ubiquitous exposure via the measurement of metabolites in urine (Silva et al. 
2004). In the Columbia Center for Children’s Environmental Health (CCCEH) study of Mothers 
and Newborns we detect metabolites of the four phthalates in >99% of prenatal and child urine 
samples (Adibi et al. 2008; See Chapter 7). Phthalate metabolites are also detected in blood, and 
breast milk (Frederiksen et al. 2007), with evidence of transplacental exposure (Wittassek et al. 
2009). The development of laboratory methods to analyze phthalate metabolites in biologic media 
has enabled a growing body of epidemiologic health studies that utilize these measures. Many of 
the current laboratory methods were first developed at the National Center for Environmental 
Health at the Centers for Disease Control and Prevention, the laboratory that analyzed phthalate 
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metabolite concentrations for these studies. These methods utilize an on-line solid-phase extraction 
coupled with high performance liquid chromatography and tandem mass spectrometry (Kato et al. 
2005). Limits of detection for the various metabolites are less than one ng/ml. Because there is no 
esterase activity in urine samples to hydrolyze parent diester phthalates to the first stage monoester 
metabolites, the concentrations of urinary metabolites are not susceptible to contamination with 
phthalates that might occur through sample collection or handling (Hauser and Calafat 2005). 
The measurement of phthalates in urine is a valuable biomarker for epidemiologic studies 
of health effects because it integrates exposure across multiple routes: ingestion, inhalation, and 
dermal absorption. This is an advantage in studies in which total uptake might be more important 
than an estimate of uptake by a single route, such as estimating prenatal exposure from biomarker 
concentrations in maternal urine. However, the inability to separate routes of exposure can be a 
limitation when investigating mechanisms of biologic effect particular to intake via a specific 
route. The contribution of each of the routes of exposure appears to vary between phthalates 
(Fromme et al. 2007; Wormuth et al. 2006), and urinary concentrations of different phthalate 
metabolites typically span orders of magnitude within a population (Silva et al. 2004). The 
variability in concentrations of phthalates in environmental media and biologic samples can arise 
from variation in the sources and concentrations, individual’s behaviors, and differences in 
metabolism and excretion. Details on metabolism, half-lives, and the reliability of the biomarkers 
are discussed in the self-contained manuscripts. 
Understanding the contribution of different sources of phthalate exposure is important for 
identifying groups with abnormally high exposures as well as designing interventions that could 
lower exposure. Prior studies looking at source contributions to phthalate exposures have provided  
limited insights but often are not able to account for the multiple routes of exposure or for the high 
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degree of variability across populations. Examples of experimental or interventional study designs 
have included topical application of a cream with a known concentration of several phthalates to 
monitor dermal uptake (Janjua et al. 2008), and measurement of urine concentration before and 
after extended fasting to evaluate dietary contribution (Wittassek et al. 2011). These designs 
provide powerful evidence through experimental manipulation but can be of limited 
generalizability as they are typically done with small sample sizes of adult volunteers. Exposure 
studies have also measured phthalate concentrations in dietary sources, consumer products and 
environmental media including dairy products (Castle et al. 1990), personal care products 
(Hubinger and Havery 2006), and indoor air and house dust (Rudel et al. 2003). Human exposures 
have been estimated by models that combine these source concentrations with time-activity data 
(Wormuth et al. 2006). Due to the high variability in exposures measured in population-based 
studies, observational studies testing associations with putative environmental sources have 
succeeded in identifying contributors to exposure or internal dose only when a particular 
source/behavior is the dominant contributor. For example, the urinary concentration of the 
metabolite mono-n-butyl phthalate was 49 times higher in the six NHANES participants reporting 
use of the polymer coated medication Mesalamine compared to the mean concentration among 
nonusers (Hernandez-Diaz et al. 2009). 
Our data and others’ indicate that exposure to lower molecular weight phthalates such as 
DEP is positively associated with use of personal care products in pregnant women (Berman et al. 
2009; Just et al. 2010), and infants (Sathyanarayana et al. 2008b). Because of their lower molecular 
weight, these phthalates are also found at higher concentrations in indoor air compared with higher 
molecular weight phthalates such as DEHP and BBzP (Adibi et al. 2008; Rudel et al. 2003). 
Models suggest that exposure to the higher molecular weight phthalates, especially DEHP, is 
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primarily dietary in adults (including pregnant women) and school age children (Fromme et al. 
2007; Koch et al. 2006; Wormuth et al. 2006). In addition, higher molecular weight phthalates used 
in consumer products, furnishings, and building materials accumulate in interior environments 
bound to particles in dust (Abb et al. 2009; Becker et al. 2004; Bornehag et al. 2005a; Fromme et 
al. 2004; Kolarik et al. 2008a; Langer et al. 2010; Rakkestad et al. 2007; Rudel et al. 2003; Rudel 
et al. 2010). The higher molecular weight phthalates, including BBzP and DEHP, have a low vapor 
phase but can be resuspended on dust particles, including respirable particles (Rakkestad et al. 
2007) by indoor air circulation. Dust and air concentrations have been shown to be correlated (Oie 
et al. 1997; Rudel et al. 2003; Xu et al. 2009). The correlation among pregnant women in the 
CCCEH cohort between personal air phthalate diesters and maternal urinary metabolite 
concentrations for several phthalates indicates that inhalation may also be an important 
contribution to exposure to certain phthalates, particularly DEP and BBzP (Adibi et al. 2003; Adibi 
et al. 2008). Our results also indicate that perfume use among pregnant women in the CCCEH 
cohort may be a potentially large source of dermal exposure to DEP (Just et al. 2010). Infants and 
toddlers have additional exposures to phthalates via ingestion of dust and hand/toy to mouth 
activity (Sathyanarayana et al. 2008a; Sathyanarayana et al. 2008b; Wormuth et al. 2006). 
 
Analyzing correlated exposure biomarkers 
The advancement of exposure science in the past decade, particularly the expansion of the 
publically available biomonitoring datasets of the National Health and Nutrition Examination 
Survey (NHANES) generated by the US Centers for Disease Control and Prevention (CDC), have 
clearly demonstrated that the general population is exposed to many potential toxins 
simultaneously (Centers for Disease Control and Prevention and National Center for Health 
9 
 
Statistics 2003-2004; Rudel et al. 2003). Exposures to related compounds that share sources and 
routes of exposure are often highly correlated. However, conventional approaches to risk 
assessment and epidemiologic analyses of health effects have generally examined one chemical at 
a time. This can lead to many statistically significant predictors without informing the investigator 
of which are driving the association. A typical regression approach favoring parsimony might use 
selection techniques (e.g. stepwise) to subset predictors as either “in” or “out” with the latter being 
forced into a coefficient estimate of zero (Greenland 1994). In addition to possibly missing the 
combined impact of individually modest effects, selection algorithms have distorted uncertainty on 
parameter estimates, particularly those that are left out (Greenland 2000). The limitations of testing 
exposures one at a time without considering the mixture have been further demonstrated in 
experimental results that show that simultaneous exposures to estrogenic compounds that are 
individually below their no observed effect concentrations can have significant additive effects 
without interaction (Silva et al. 2002). In contrast with one at a time models, analytic techniques 
that model multiple correlated dosimeters simultaneously using maximum likelihood regression 
can lead to unstable effect size estimates. This problem of correlation of predictor variables in 
multiple regression is termed multicollinearity. An alternative approach for correlated predictors is 
to combine predictors to create summary score measures by manually fixing the additive weights 
applied to each component based on prior knowledge. Unfortunately, the resulting score doesn’t 
allow estimation of the effects of individual components and prediction with such scores is 
sensitive to the weights that are selected. In addition to a loss of information, this often requires an 
assumption of additivity and a weighting scheme derived from laborious toxicologic work which 
must explicitly test the relative potency of each compound against a standard. Additional 
uncertainty in such weights arises from the use of experimental systems with subjective selection 
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of relevant endpoints as well as high-to-low dose and animal to human extrapolation (Kortenkamp 
2007) 
Because of all of these analytic challenges, an expert consensus report from the National 
Research Council called upon regulators to take new approaches to cumulative risk assessment and 
examine mixtures rather than considering environmental contaminants with common targets or 
modes of action one at a time (Committee on the Health Risks of Phthalates 2008). Further, the 
report recommended that new methods be developed using phthalates as a model system.  
Bayesian approaches can estimate the relative weighting of each of the predictors within 
epidemiologic datasets. Details on the structure and theory of these models are discussed in detail 
in Chapter 5. Bayesian models have seldom been used for assessing effects of multiple exposures 
in the environmental health sciences, despite earlier calls for doing so (Greenland 1994). A 
noteworthy exception is a recent application of Bayesian hierarchical methods to the association 
between exposure to 18 herbicides and retinal degeneration under different modeling assumptions. 
However, the exposure information in this study was derived from a questionnaire and exhibited 
only moderate correlations that ranged from 0.06 to 0.58 (MacLehose et al. 2007). Although 
epidemiologists can use data augmentation for Bayesian modeling within popular software 
packages like SPSS and SAS (Greenland 2007), the widely available Bayesian inference Using 
Gibbs Sampling (WinBUGS) freeware makes more sophisticated models available for new 
applications without sophisticated programming (Lunn et al. 2000). Adapting these statistical 
models for the environmental health sciences and demonstrating improved performance over 
conventional methods could lead to their wider use and consequently address the gap in 




Health outcomes: allergy and asthma burden in children 
The natural progression of childhood allergy and asthma is often referred to as the “atopic 
march” in which early eczema and atopy lead to allergic rhinitis and atopic asthma as a common 
pathway to childhood asthma (Leung et al. 2004; Zheng et al. 2011). Eczema, a chronic 
inflammatory skin disease characterized by pruritic rashes on the skin, can develop early in life 
with both allergic and other environmental triggers (Eigenmann et al. 1998; Leung et al. 2004; 
Novak and Bieber 2003; Novembre et al. 2001; Schmid-Grendelmeier et al. 2001). While eczema 
is often referred to as atopic dermatitis, as many as two-thirds of children with eczema are non-
atopic in population based studies (Flohr et al. 2004). There is some evidence that eczema may 
predispose to allergic sensitization through disruption of epithelial barriers (Flohr 2011), which 
differs from a more classical characterization of eczema as an allergic disease but still would 
explain the stronger relation seen between severe eczema and multiple allergic sensitization 
(Novak and Bieber 2003; Schafer et al. 1999).  
Incidence and prevalence of childhood allergic diseases and asthma increased substantially 
over the second half of the 20th century, particularly in westernized nations and their urban centers 
(Asher et al. 2006; Eder et al. 2006). This is partially attributed to increasing environmental 
exposures including to environmental tobacco smoke (ETS), aeroallergens, combustion 
byproducts, as well as decreased microbial exposure (Eder et al. 2006; Pearce et al. 2007). The 
varying prevalence of allergic diseases and asthma within ethnic groups and geographic regions 
and the increase in these diseases over a time span of decades both suggest the contribution of 
environmental factors. The asthma increase also corresponds temporally and geographically with 
the widespread production and use of phthalates in consumer products (Bornehag et al. 2004). The 
burden of disease is not evenly distributed; higher prevalence is noted in urban areas particularly in 
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poorer neighborhoods and among African American and Hispanic populations. A similar pattern is 
also reported for eczema in children with a higher prevalence in urban and African American 
households (Shaw et al. 2011). In 2000, asthma hospitalizations (which reflect disease severity and 
access to healthcare) among children in New York City were almost twice as high as those 
reported for the United States as a whole (Garg et al. 2003). In the CCCEH cohort, 26%, 25%, and 




FeNO is an easily collected marker of airway inflammation, a critical process in the 
pathogenesis and subsequent exacerbation of asthma. Higher FeNO precedes new-onset wheeze 
(Olin et al. 2010), and is higher among children with more frequent wheeze than less frequent 
wheeze (Cornell et al. accepted 2011). FeNO is also higher among atopic children and varies with 
exposure to allergen (Sordillo et al. 2011). Recent work has shown that FeNO measures collected 
at a single exhalation rate combine components of FeNO that are correlated with both atopy and 
wheeze that these are separable after collection at multiple flow rates (Rosa et al. 2011). FeNO has 
been shown to increase in both asthmatics and non-asthmatics after exposure to components of 
traffic related pollution as well as indoor pollutants such as formaldehyde (Cornell et al. accepted 
2011; Eckel et al. 2011; Franklin et al. 2000; McCreanor et al. 2007). Because FeNO can be 
collected reliably in young children it is increasingly being utilized as a biomarker to study sub-




Epidemiologic evidence on phthalates, allergic disease, and respiratory health 
Recent epidemiologic studies suggest an association between home environments 
containing phthalates (measuring exposure indirectly) and increased symptoms of allergy and 
asthma in children. In a Finnish cross-sectional study based on parental report, children living in 
homes with plastic wall materials experienced a 3.42 (95% CI 1.13 to 10.36) increased odds of 
reported persistent wheeze (Jaakkola et al. 2000). Elevated odds ratios were also seen for report of 
cough and phlegm. In a Finnish case-control study of 251 bronchial-obstructed children with age-
matched controls, children living in residences with PVC flooring had an OR of 1.89 (95% CI 1.14 
to 3.14) relative to the reference category of wood or parquet flooring (Jaakkola et al. 1999). Both 
studies lack any direct phthalate exposure measurements.  
Environmental levels of phthalates were measured in a Swedish case-control study 
comparing children with reported persistent eczema, rhinitis, or wheezing without a cold, to 
children without symptoms. Median concentrations of BBzP in bedroom dust were higher among 
cases than controls and in children with versus without physician-diagnosed rhinitis and eczema 
(Bornehag et al. 2004). Although rhinitis and eczema have both been classically considered 
allergic diseases (Flohr et al. 2004), there was no difference in the mean bedroom dust 
concentration of BBzP between atopic and non-atopic cases (Bornehag et al. 2004). PVC flooring 
was also significantly associated with case status. DEHP in dust was associated with physician-
diagnosed asthma and showed a dose-response relationship across quartiles of exposure. In the 
adjusted analysis, the odds of physician diagnosed asthma were 2.93 (95% CI 1.36 to 6.34) times 
greater among those in the highest quartile of exposure compared to those in the lowest quartile 
(Bornehag et al. 2004). This study design was replicated in Bulgaria. Higher DEHP concentrations 
were found in bedroom dust of cases compared with controls with a dose-response in the odds of 
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being a case across quartiles of exposure. In the study in Bulgaria, BBzP was non-significantly 
higher in the dust of those reporting wheeze or eczema (Kolarik et al. 2008b). 
There remains a lack of studies examining the association between biomarkers of 
phthalates and objective measures of children’s pulmonary outcomes. In an NHANES III cross-
sectional analysis examining adults, urinary metabolites of DBP and DEP were associated with 
decrements in pulmonary function tests only among males (Hoppin et al. 2004). A cross-sectional 
analysis in girls aged 6-8 in New York City found associations between metabolites of high 
molecular weight phthalates in urine and report of doctor diagnosed asthma and asthma related 
symptoms (Teitelbaum et al. 2008). 
Two major limitations plague studies of phthalate exposure and respiratory outcomes (see 
our review (Kwak et al. 2009) and others (Jaakkola and Knight 2008; Mendell 2007; Nielsen et al. 
2007)). First, indirect exposure measures such as recording the presence of materials in the home 
or measuring phthalates in house dust (Bornehag et al. 2004; Jaakkola et al. 1999; Jaakkola et al. 
2000; Kolarik et al. 2008b), can lead to misclassification of exposure and likely would bias studies 
toward the null. Second, the lack of a prospective design prevents determination of causality. 
Retrospective or cross-sectional studies lack temporal ordering of exposures prior to disease. 
Therefore they cannot preclude, for example, that observed associations may be due to reverse 
causality (Bornehag et al. 2005b). This order of events might plausibly occur if parents of 
asthmatic children attempted to reduce the presence of airborne triggers for asthma by replacing 




Toxicologic evidence on phthalates, allergy, and respiratory health 
Although the proposed mechanism for the role of phthalates in asthma and respiratory 
health is still unclear, the strongest toxicologic evidence suggests some phthalates, particularly 
DEHP, may act as adjuvants (but not intrinsic allergens (Butala et al. 2004)) enhancing the 
immune and allergic response (Larsen et al. 2002). Phthalates may contribute to airway 
inflammation by enhancing IgE-mediated type I hypersensitivity to common aero-allergens. Two 
inhalation adjuvant studies on BALB/cJ mice found increases in IgG1 but not IgE after coexposure 
to ovalbumin and either inhaled DEHP or its metabolite MEHP (Hansen et al. 2007; Larsen et al. 
2007). IgG1 is often used as a surrogate marker for Th2 responses in mice which regulate it 
similarly to IgE (Dearman et al. 2009). In a different strain of atopic prone mice, splenocytes 
stimulated ex-vivo with DEHP have enhanced differentiation and Th2 type responses (secretion of 
IL-4) (Koike et al. 2009). In BALB/c mice first primed with a novel antigen, keyhole limpet 
hemocyanin (KLH), and alum, the ex-vivo addition of DEHP or another phthalate DiNP with KLH 
enhanced Th2 type responses (IL-4 and not IFN-γ) in a dose-dependent fashion in lymph node 
cells. The experiment showed that this was due to CD4+ T cells which had upregulated IL-4 gene 
expression. This resulted in dose-dependent enhanced production of total and KLH specific IgE for 
both phthalates compared to KLH stimulation alone (Lee et al. 2004). Incubating human peripheral 
blood mononuclear cells with DEHP or its metabolite MEHP ex-vivo potentiated an increased 
histamine release (2-3x) after stimulation with another allergy promoting factor and the addition of 
cross-linking anti-IgE compared with controls (Glue et al. 2005). DEHP and DBP also act as 
adjuvants enhancing the development of atopic dermatitis with exposure to dust mites 
(Yanagisawa et al. 2008) or a chemical hapten (Shigeno et al. 2009) in two mouse models of 
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allergy formation. In contrast with these other phthalates, BBzP does not appear to have adjuvant 
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 Diethyl phthalate (DEP) and di-n-butyl phthalate (DnBP) are used extensively in personal 
care products, including fragrances (DEP) and nail polish (DnBP). Between May 2003 and July 
2006, we gathered questionnaire data on use of 7 product categories (deodorant, perfume, hair 
spray, hair gel, nail polish/polish remover, liquid soap/body wash, lotion/mist) over 48 hours 
during the 3rd trimester of pregnancy from 186 inner-city women. A 48-hour personal air sample 
was collected and analyzed for DEP and DnBP; a maternal spot urine sample was collected and 
analyzed for their monoester metabolites, monoethyl phthalate (MEP) and mono-n-butyl phthalate 
(MnBP), respectively. Ninety-seven percent of air samples and 84% of urine samples were 
collected within ±2 days of the questionnaire. During the 48 hours, 41% of women reported 
perfume use and 10% reported nail polish/polish remover use. In adjusted analyses, no association 
was seen between nail product use and air DnBP or urine MnBP concentrations. Women reporting 
perfume use had 2.3 times higher (95% CI 1.6, 3.3) urinary MEP concentrations. Personal air DEP 
increased 7% for each 25% increase in a composite indicator of the 6 other product 
categories (p<0.05) but was not associated with perfume use. Air DEP was correlated with urine 
MEP concentrations only among non-perfume users (r=0.51, p<0.001). Results suggest that 
perfume use is a significant source of DEP exposure.  
 







 Phthalates are diesters of phthalic acid that are commonly used in a wide variety of 
consumer products. Human exposures come from their use in toys, household materials, medical 
devices, in the processing and packaging of foods, and personal care products (Schettler 2006). 
Some phthalates are under increasing scrutiny in epidemiologic studies examining potential 
associations with adverse reproductive and developmental outcomes including changes in 
gestational age, urogenital tract development, sperm quality, and asthma among other endpoints 
(Swan 2008). However, relatively few studies have examined the relation between sources, 
exposure pathways, and internal dosimeters.  
Two phthalates, diethyl phthalate (DEP) and di-n-butyl phthalate (DnBP), are added as a 
solvent for fragrances or to prevent products from becoming brittle, and have been found at higher 
concentrations than other phthalates in testing of personal care products in the United States, South 
Korea, and China (Houlihan et al. 2002; Hubinger and Havery 2006; Koo and Lee 2004; Shen et 
al. 2007). Among personal care products, DEP and DnBP have been found at the highest 
concentrations in fragrance products, including perfume (DEP), and in nail polishes (DnBP). 
Figure 1 shows an adaptation of results from the analysis of DEP in 48 personal care products in 
the United States (Hubinger and Havery 2006). The five fragrance products tested had 
concentrations of DEP ranging from 5486 to 38663 ppm, and the next highest DEP concentration 
of any other product tested was in a deodorant with 2933 ppm (Hubinger and Havery 2006). In 
these data, fragrances have consistently higher concentrations of DEP compared with all other 
products tested, supporting the separate analysis of perfume from other personal care product 
categories as potential sources of DEP. According to a review of patent records, nail polishes 
might contain 50000 ppm (5%) DnBP (Houlihan et al. 2002), a finding that was supported by a 
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study that tested six nail enamel products and found concentrations that ranged from below the 
limit of detection to 59815 ppm, or roughly 6% (Hubinger and Havery 2006). Thus, nail polishes 
should be analyzed separately from other categories of personal care products as potential sources 
of exposure to DnBP because nail polishes appear to be more likely to contain DnBP and at higher 
concentrations than other product categories. Under current regulations in which ingredients used 
in fragrances are exempt from disclosure, phthalates are not generally listed as ingredients on 
consumer products in the United States (Steinemann 2009). 
 
 
Figure 1. Diethyl phthalate in personal care products 
Adapted from Table 2 of Hubinger and Havery, 2006. A total of 48 products purchased in the 
Washington, DC area were tested. Non-detectable values are displayed as less than the limit of 
detection of 10ppm. Hand cream (n=2) and shampoo (n=1) are not shown. No direct product 
testing took place in the current study. 
 
Phthalates can enter the body via ingestion, dermal absorption, parenteral intake from 
medical devices, and inhalation. They undergo rapid hydrolysis to monoesters; short-alkyl chain 
phthalates like DEP and DnBP are principally excreted in the urine as hydrolytic monoesters or as 
their corresponding glucuronidated conjugates (Silva et al. 2003). In 16 human volunteers who 
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ingested a labeled dose of DnBP, 69% was excreted as mono-n-butyl phthalate (MnBP) in urine 
with undetectable levels of urinary MnBP after the first 24 hours (Anderson et al. 2001). Half-lives 
of DEP were similarly short in animal studies (Api 2001). Both DEP and DnBP are also taken up 
dermally with an estimated 6% and 2% respectively excreted as their urinary metabolites 
monoethyl phthalate (MEP) and MnBP by human volunteers after dermal application (Janjua et al. 
2008). The majority of dermally absorbed DEP was excreted within 8 hours and MnBP excretion 
lagged slightly compared to MEP but was largely excreted within 24 hours. Urinary MEP 
concentrations from a representative sample of the US population (National Health and Nutrition 
Examination Survey [NHANES] 1999-2000) were highest at a midday collection which was 
hypothesized to be related to the application of personal care products in the morning (Silva et al. 
2004). 
Some evidence already exists for an association between frequency of personal care 
product use and urinary concentrations of phthalates. Men reporting the use of cologne or 
aftershave over 48 hours had higher urinary MEP concentrations than other men (Duty et al. 2005). 
Another study reported an association between the use of baby care products and concentrations of 
MEP and two other phthalate metabolites but not MnBP in infant urine samples (Sathyanarayana et 
al. 2008). An increase in the number of personal care products used in the previous 48 hours was 
associated with higher urinary MEP in 19 pregnant women in Israel (Berman et al. 2009). Work as 
a manicurist in a nail-only salon was associated with urinary concentrations of MnBP in two 
occupational studies among nail-only salon workers. Urinary MnBP concentrations post-shift were 
49% higher than pre-shift in 37 manicurists from Massachusetts in 2004-2005 (Kwapniewski et al. 
2008). In 26 manicurists in Maryland studied between 2003 and 2005, those using gloves had 50% 
lower post-shift MnBP concentration compared to non-users (Hines et al. 2009). Collectively, 
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these five studies indicate the potential importance of dermal absorption for exposures to DEP and 
DnBP and the suitability of urinary metabolites to assess these exposures. 
We have reported previously that DEP and DnBP and their metabolites were found in 
100% of personal air and urine samples collected from inner-city women during pregnancy (Adibi 
et al. 2008). The purpose of the current study was to determine if personal care product use was 
associated with measures of phthalate exposure in air and urine samples among the same urban 
cohort of pregnant women. To do this, we evaluated the relationship between self-reported prenatal 
personal care product use and concentrations of DEP and DnBP in personal air samples and MEP 
and MnBP in urine samples. The particular focus was on perfume and nail product use and 




Participants (n = 186) were selected from the Mothers and Newborns cohort study of the 
Columbia Center for Children’s Environmental Health (CCCEH) based in Northern Manhattan and 
the South Bronx, New York (Perera et al. 2003; Whyatt et al. 2003). Selection was based on the 
availability of a product use questionnaire and phthalates measured within a week in either a 
personal air and/or urine sample collected during the third trimester of pregnancy. Overall 97% of 
air samples and 84% of urine samples were collected within two days of the product-use 
questionnaire. In most cases there was no difference when analysis was limited to the subsets 
within two days and results are given for the whole cohort unless otherwise specified. Enrollment 
criteria for the CCCEH cohort have been described elsewhere (Perera et al. 2003; Whyatt et al. 
2003). The study was restricted to women 18-35 years old who self-identified as either African 
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American or Dominican and had resided in Northern Manhattan or the South Bronx for at least one 
year prior to pregnancy. Women were excluded at enrollment if they reported that they smoked 
cigarettes or used other tobacco products during pregnancy, used illicit drugs, had diabetes, 
hypertension or known HIV, or had their first prenatal visit after the 20th week gestation. Study 
procedures, including questionnaires, personal air monitoring and collection of biologic samples, 
were explained to each subject at enrollment and a signed consent, approved by the IRB of 
Columbia University and the Centers for Disease Control and Prevention (CDC), was obtained. 
 
Product use questionnaire 
A brief questionnaire that was administered in the third trimester (mean gestational age 35 
weeks) asked participants to recall their use of various types of personal care products over the 
previous 48 hours and throughout the individual trimesters of pregnancy. They were asked about 
use (yes/no), the number of total uses over 48 hours, and the frequency of use during each trimester 
(>1/day, 1/day, 2-3/week, 1/week, <1/week-1/month, <1/month). From the questionnaire, we 
selected seven product categories for this analysis: deodorant, lotion or mist (spray application), 
perfume, liquid soap or body wash, hair gel, hair spray, and nail polish or polish remover. Because 
the questionnaire asked about nail polish or polish remover together, we refer to this category as 
nail products. The product categories selected were those likely to contain DEP or DnBP and 
which were used by ≥ 10% of participants. Six and 20 participants were missing information on the 




Sample collection and analysis 
Participants carried backpacks for 48 hours containing pumps drawing personal air samples 
at 4 L/min from near the breathing zone onto a quartz filter with a polyurethane foam cartridge 
backup. Air samples were stored in a freezer and shipped on dry ice to Southwest Research 
Institute (San Antonio, Texas) for extraction and analysis of phthalates via gas chromatography / 
mass spectrometry (Adibi et al. 2008). Laboratory matrix blanks were extracted and analyzed with 
each batch of samples, to assess laboratory-introduced phthalate contamination. Although DEP and 
DnBP were often detected, concentrations in the laboratory blanks (n=53) were substantially lower 
than personal air extracts (average of 993 ± 2617 versus 24838 ± 23047 ng/extract for DEP and 
288 ± 263 versus 6325 ± 5963 ng/extract for DnBP). Personal air samples were collected for 168 
of 186 participants (90%). 
A spot urine sample was collected generally at the start or conclusion of the 48 hour 
personal air monitoring. The date, but not exact time of collection, was available. The urinary 
concentrations of nine phthalate metabolites, including MEP and MnBP, were measured at the 
National Center for Environmental Health, CDC. Urine samples underwent an enzymatic 
deconjugation reaction followed by solid-phase extraction; the phthalate metabolites were 
separated with high-performance liquid chromatography, and detected with isotope-dilution 
tandem mass spectrometry as described previously (Adibi et al. 2008; Kato et al. 2005). The limits 
of detection (LODs), which varied slightly depending on the method used, were in the low ng/ml 
range. Specific gravity was measured at room temperature at the CDC with a handheld 
refractometer. Urinary concentrations were adjusted for dilution in statistical analysis using a 
formula from Hauser et al. adapted with a constant that is more appropriate for urinary dilution 
during pregnancy (Hauser et al. 2004; Teass et al. 1998). The constant value is derived from the 
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median specific gravity of pregnant women in the CCCEH cohort study. The formula is Pc = 
P[(1.016-1)/(SG-1)], where Pc is the specific-gravity-corrected phthalate concentration, P is the 
observed phthalate concentration and SG is the specific gravity of the urine sample. Urine samples 
were collected for 164 of 186 participants (88%).  
Air and urine samples were collected between May 2003 and July 2006. Extracts from air 
samples were analyzed between January 2006 and November 2007. Urine samples were analyzed 
between 2004 and 2007.  
 
Statistical methods 
For personal air concentrations of DEP and urinary concentrations of MEP, perfume use 
was examined separately from the other products. We aggregated data on other products used by 
summing the reported number of product uses over the 48 hour period for the other six product 
categories. For analytical purposes we then assigned study subjects to quartile categories across the 
distribution of summed product uses. For example, a participant reporting, of the six categories, 
one use of hair gel, one use of liquid gel, two uses of lotion, and two uses of deodorant would have 
six total uses which would put them in the second quartile for use of other products. For analyses 
of DnBP and MnBP, nail products were examined separately and the use of other products was 
similarly summed and classified into quartiles. All statistical tests on urinary and air measures were 
conducted with natural logarithm transformed concentrations after adjustment of urine data for 
specific gravity. Assumptions of normality were assessed visually with quantile-quantile plots. 
Correlation tests used Pearson’s correlation coefficient. Simulation using informal Bayesian 
inference with uniform priors was used to graph uncertainty in regression parameters. For visual 
interpretation, this displays ~95% of simulation draws of regression slopes within two standard 
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errors for each parameter estimate (Gelman and Hill 2007). Differences in group means were 
assessed with Student’s t-test or with a multiple partial F-test for indicator variables in 
multivariable linear regression when controlling for covariates. Model building began with 
unadjusted models including only exposure variables derived from the product use questionnaire. 
The full model included demographic covariates, selected to be consistent with prior research, for 
race/ethnicity, age, education, and BMI that might contribute to confounding or increase 
explanatory power (Duty et al. 2005). Unadjusted models had similar results to the multivariable 
results presented here. The quartiles of product use variables were first assessed with a series of 
three indicator variables relative to the lowest quartile to evaluate the assumption of monotonicity 
and then if appropriate used in multivariable regression as a continuous measure. Parameter 
estimates from regression were exponentiated and presented as fold-changes. The coefficient of 
determination, R2, was examined as the proportion of the variance in the outcome explained by the 




Sample size, demographics, and reported product use 
Participant characteristics for the 186 women are detailed in Table 1. Those who were 
missing an air or urine sample did not differ on demographic characteristics from the remainder. 
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Table 1. Characteristics of 186 pregnant study participants 
Age (years)1 26 ± 5 
Ethnicity (%)  
African American 28 
Dominican or other Hispanic 72 
Education (%)  
High school diploma, GED,  
or greater 
61 
Body Mass Index1 27 ± 7 
Maternal ETS  
% reporting smoker in the home 25 
Reported use (yes versus no) of 
categories of personal care products 





Liquid soap 29 
Hair gel 25 
Hair spray 10 
Nail polish or polish remover 10 
1Mean ± standard deviation 
 
Product use 
Participants reported using an average of 3 product types of the seven categories in this 
analysis. The median for the total number of times the women used any product was 7 with a range 
from 1 to 26 (n = 180). Table 1 lists the frequency of reported use of the product categories in the 
48 hour period. Deodorant was the product category with the most prevalent use (98%). The most 
frequently used product category was liquid soap (mean of 3.4 uses in 48 hours among participants 
reporting use of that product), followed by lotion and deodorant. Perfume use in the 48 hour period 
of the questionnaire was reported by 41% of participants and was higher among African 
Americans (45%) than among Dominicans (40%) although the difference in proportions was not 
significant. Perfume users had a median of 2 reported uses over the 48 hour period. Overall, 84% 
reported using perfume at some point throughout their pregnancy and those reporting usage in the 
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48 hour period during the third trimester, were more likely to report having used perfume in the 
first two trimesters (chi-squared 17.2 1 degree of freedom (DF), p < 0.01). In the 166 participants with 
information about frequency of use in the third trimester, 61 reported using perfume at least daily 
(37%). The proportion reporting at least daily use in the third trimester was higher among those 
reporting perfume use in the 48 hour period (63%) compared with those not reporting perfume use 
in the 48 hour period (17%) (chi-squared 34.4 1 DF, p < 0.001). There was no association between 
perfume use (yes/no) and quartiles of the total uses of the other six product categories (n = 180, 
chi-squared 1.4 3 DF, p = 0.7). Use of nail products over the 48 hours was reported by 10% of 
participants (18 of n = 186). Nail product users all reported a single use over the 48 hour period. 
Overall, 69% of participants reported using nail products at some point throughout their pregnancy 
and those reporting usage in the 48 hour period in their third trimester were more likely to report 
having used nail products in the first two trimesters (chi-squared 7.2 1 DF, p < 0.01). There was no 
difference in the quartile of the sum of product uses between African American and Dominican 
participants (n = 180, chi-squared 0.5 3 DF, p = 0.92).  
 
Personal air and urinary metabolite concentrations 
DEP and DnBP were detected in 100% of air samples (n = 168) and MEP and MnBP were 
detected in 100% of urine samples (n = 164). The distribution of phthalates in personal air and 
metabolites in urine are summarized in Table 2. We did not see a temporal trend from 2003 to 
2006 in concentrations of DEP and DnBP in personal air samples or MEP and MnBP in urine in a 




Table 2.  Distribution of phthalate diester concentrations in personal air (ng/m3) and metabolite 












50th 75th 95th 
(ng/m3)         
DEP  100 747 1276 1730 2532 4346 1816 (1668 to 1977) 
DnBP  100 206 310 449 626 1077 459 (421 to 499) 
 (ng/mL)        
 MEP 100 37 103 199 489 3184 243 (198 to 298) 
 MnBP 100 6 20 36 84 203 38 (32 to 45) 
GM, geometric mean; LOD, limit of detection 
1Personal air concentrations of phthalates were available for n = 168. 
2Urinary metabolite concentrations of phthalates were available for n = 164. 
 
Air and urine concentrations of phthalates and their metabolites were correlated. The 
correlation of DEP and MEP (n = 146, r = 0.36, p < 0.001) was similar to the correlation for DnBP 
and MnBP (r = 0.32, p < 0.001). Correlations were similar when restricted to urine samples 
collected within ±2 two days of the conclusion of the 48 hour personal air sample (n = 126, DEP 
and MEP, r = 0.36, p < 0.001; DnBP and MnBP, r = 0.31, p < 0.001). The concentrations of the 
two metabolites MEP and MnBP were also correlated (r = 0.40, p < 0.001) as were the 
concentrations of the two parent compounds, DEP and DnBP, in the personal air samples (r = 0.33, 
p < 0.001). There appeared to be no correlation between DEP and MnBP (r = 0.04, p = 0.62) or 
between DnBP and MEP (r = 0.11, p = 0.20). 
African Americans had higher concentrations of DEP in their personal air with a geometric 
mean that was 56% higher than among Dominicans (t-test, p < 0.001). The adjustment for 
individual product categories, including perfume, or for counts of the number of categories of 
potentially DEP containing product types or categories of other hair products did not explain this 
difference (data not shown). Although urinary concentrations of MEP were higher among African 
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Americans than Dominicans (geometric mean 55% higher, t-test, p=0.07), the difference was of 
borderline significance. 
Results from the adjusted analyses of the relationship between product use and both DEP in 
personal air and MEP in maternal urine are presented in Table 3. There was no association between 
perfume use and air DEP concentrations. However, DEP increased by 7% for each quartile 
increase in the sum of uses of the other six products (p < 0.05). Perfume use was significantly 
associated with MEP concentration in urine samples. Specifically, women reporting perfume use in 
the 48 hour questionnaire period had 2.3 times higher concentrations of urinary MEP than those 
not reporting use in the same period (95% CI 1.6 to 3.3, p < 0.001). Further, controlling for 
perfume use, there was a significant association between quartiles of use of the other six products 
and urinary MEP concentration (a 26% increase in MEP concentrations for each quartile increase 
in the sum of product uses, p < 0.01). The full model explains 19% of the variance in urinary MEP. 
To further evaluate the dose-response relationship between perfume use and urinary MEP, analyses 
were restricted to subjects with urine collected within two days of the questionnaire (n = 128). 
Results are presented in Figure 2 and show a dose-response relation between urinary MEP and 
reported number of times perfume was used over the 48-hour period after adjustment for 
race/ethnicity (t-test on regression coefficient for continuous measure, p < 0.001). We also 
examined the correlation between DEP in air and MEP in urine in the same subset of study 
participants. Interestingly, among perfume users there was no correlation (n = 57, r = 0.12, p = 
0.36). However, among non-perfume users, the correlation was highly significant and stronger than 




Table 3. Multivariable regression results for association of product use and covariates with 
personal air DEP and urine MEP concentrations 
 DEP (n = 163; R2 = 0.19) 
MEP 
(n = 160; R2 = 0.19) 
 Fold change (95% CI) Fold change (95% CI) 
Perfume use1  1.09  (0.9 to 1.3) 2.29  (1.6 to 3.3)***  
Quartile of use of 
other products2  
1.07  (1.0 to 1.2)* 1.26  (1.1 to 1.5)** 
Race/ethnicity3  1.53  (1.3 to 1.8)*** 1.22  (0.8 to 1.8) 
Age (years)  0.99  (1.0 to 1.0) 0.98  (0.9 to 1.0) 
Education4  0.96  (0.8 to 1.1) 1.31  (0.9 to 1.9) 
BMI5  1.00  (1.0 to 1.0) 1.02  (1.0 to 1.0) 
*p-value < 0.05; ** < 0.01; *** < 0.001 
1 0 = no use in previous 48 hour period; 1 = yes. 2 quartiled sum of uses in 48 hour period of 
deodorant, lotion, liquid soap, hair gel, hair spray, and nail polish/remover. 3 0 = Dominican; 1 = 
African American. 4 0 = no high school degree or equivalent; 1 = high school degree or greater. 5 
Pre-pregnancy body mass index (kg/m2). 





Figure 2. Log urinary MEP concentrations (adjusted for specific gravity) for participants 
with 0 to 4 reported uses of perfume over a 48 hour period and samples collected within two 
days of the questionnaire controlling for race/ethnicity (n = 137).  
Group means shown with dashed rectangles indicating 95% CI. The dotted line extends the group 
mean for non-users. The group means for those using perfume 2, 3, or 4 times are all higher than 






Figure 3. Association between DEP concentrations in personal air and the urinary metabolite 
MEP concentrations (adjusted for specific gravity) stratified by perfume use using linear 
regression of log transformed values.  
Lighter lines represent predictive uncertainty in regression parameters from informal Bayesian 
simulations (20 simulation draws with uniform priors). Boxplots show the distribution of MEP 
with means (“X”). 
 
Participants reporting use of nail products had no differences in DnBP concentrations in 
their personal air (n=16) compared with non-users (n=152), (geometric mean and 95%CI, 392 (292 
to 521) versus 466 (427 to 510) ng/m3 DnBP). Similarly, those reporting use had no differences in 
MnBP concentrations in their urine (n=16) compared with non-users (n=148) (geometric mean and 
95% CI, 42 (27 to 64) versus 39 (34 to 45) ng/ml). As shown in Table 4, there was no association 
between reported use of nail products or the composite indicator of the use of other products and 
either DnBP in personal air or MnBP in urine. Additionally, none of the other covariates were 
significant predictors of either DnBP or MnBP concentration and the regression models explained 




Table 4. Multivariable regression results for association of product use and covariates with 
personal air DnBP and urine MnBP concentrations 
 DnBP (n = 163; R2 = 0.05) 
MnBP 
(n = 160; R2 = 0.04) 
 Fold change (95% CI) Fold change (95% CI) 
Nail polish/ 
remover use1  
0.84 (0.6 to 1.1)  1.08 (0.7 to 1.7)  
Quartile of use of 
other products2  
1.05 (1.0 to 1.1)  0.96 (0.9 to 1.1)  
Race/ethnicity3  0.95 (0.8 to 1.2)  0.78 (0.6 to 1.1)  
Age  0.99 (1.0 to 1.0)  0.98 (1.0 to 1.0)  
Education4  0.87 (0.7 to 1.1)  1.05 (0.8 to 1.4)  
BMI5  1.00 (1.0 to 1.0)  1.02 (1.0 to 1.0)  
*p-value < 0.05; ** < 0.01; *** < 0.001 
1 0 = no use in previous 48 hour period; 1 = yes. 2 quartiled sum of uses in 48 hour period of 
deodorant, lotion, liquid soap, perfume, hair gel, and hair spray. 3 0 = Dominican; 1 = African 
American. 4 0 = no high school degree or equivalent; 1 = high school degree or greater. 5 Pre-
pregnancy body mass index (kg/m2). 




The use of personal care products was common during pregnancy among women in this 
urban cohort study. Participants used multiple products and many used perfume on a daily basis in 
the third trimester of pregnancy. Nail product use, while common throughout pregnancy, was less 
frequent than other categories of personal care product use.  
Perfume use over a 48 hour period was associated with increased concentrations of MEP, 
the urinary metabolite of DEP. Women who reported using perfume had on average 2.3 times 
higher concentrations of urinary MEP after adjustment for urinary dilution and covariates in a 
multiple regression analysis. Our results further show a significant dose-response relationship 
between the number of perfume uses in a 48 hour period and urinary concentration of MEP. 
Increased use of other product types (deodorant, lotion or mist, liquid soap or bodywash, hair gel, 
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hair spray, and nail products) was associated with higher concentrations of DEP in air and MEP in 
urine. 
 While perfume use was associated with urinary MEP, we found no association between 
use and DEP in personal air sample. This lack of association was unexpected as we had 
hypothesized that DEP would volatilize during perfume use and contribute to inhalation exposures. 
It is entirely possible that the lack of association is a result of limitations in the available dataset. 
However, another possible explanation is that the contribution of perfume use to total exposure 
comes more from dermal uptake than inhalation. Further, if perfumes, which have higher 
concentrations of DEP than other personal care products, contributed substantially to total 
exposure and did so primarily via dermal uptake, it might explain why there was no correlation 
between air DEP and urinary MEP among perfume users. In contrast, among non-perfume users 
there was a relatively strong correlation between air DEP and urinary MEP suggesting that the 
backpack monitors were useful in measuring exposures via inhalation. This association, although 
not a pharmacokinetic model to quantify the mass-balance contribution of inhalation, is consistent 
with inhalation as a pathway of exposure to some product categories. A shorter time frame of 
exposure monitoring, coordinated to capture episodic events, might have been a better sampling 
design for detecting associations with episodic high exposures. However, these data are not 
generally available in observational studies, including in the current cohort, in which 48 hour 
personal air samples were collected in order to characterize the exposure profile of the late 
pregnancy period. 
The classification of participants into quartiles of the use of non-perfume product types 
serves as a crude indicator for some of these sources (particularly personal care products). This 
approach increased our statistical power to detect associations; however at the expense of 
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sensitivity to identify specific sources. The combined variable was positively associated with both 
DEP in personal air and MEP in urine. In comparing personal air and urinary exposure, it is 
important to note that participants were told to keep the backpack monitor out of the bathroom 
while they showered to avoid humidity that could damage the pump. We cannot discount that this 
may have had an impact on the association between product use and the collection of personal air 
samples. However, the association of the composite indicator for non-perfume product types such 
as hair spray and lotion, which are also products likely to be used in the bathroom, with DEP in 
personal air suggests that personal air monitoring was sampling exposure events resulting from the 
use of personal care products. Perfume use may represent a greater contributor to DEP exposure 
than other personal care products. This is consistent with the substantially higher detection 
frequencies and concentrations of DEP found in perfumes compared with other product types 
(Houlihan et al. 2002; Hubinger and Havery 2006; Koo and Lee 2004; Peters 2005; Shen et al. 
2007). However, reports of perfume use, even among those with a daily use pattern, may be too 
imperfect a measure of exposure to detect differences in personal air DEP given the limitations of 
this dataset. 
There was no association between reported use of nail products or the quartiles of usage of 
other products over the previous 48 hours with concentration of either DnBP in personal air or 
MnBP in urine samples. Further, our study did not identify any significant predictors of DnBP or 
MnBP concentration. However, the proportion of nail product users was small (10%) and our 
questionnaire was designed to characterize use patterns and grouped the use of nail polish and 
polish remover together. In addition, DnBP concentrations in nail polish may vary in concentration 
more than that of DEP in perfume. In one study that sampled six off-the-shelf nail enamel 
formulations in the United States, the concentrations of DnBP ranged from less than 10 to 59815 
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ppm (Hubinger and Havery 2006). In addition, some products are being reformulated to remove 
phthalates and the prevalence of phthalates in nail polish may be changing (Hubinger and Havery 
2006). Thus, a questionnaire alone might be insufficient to assess potential exposure to DnBP 
among personal users of these products. In contrast, two occupational studies of nail-only salon 
workers found associations between shift work and exposure to DnBP as measured by urinary 
MnBP (Hines et al. 2009; Kwapniewski et al. 2008). 
We have reported previously on the distribution of phthalate concentrations in personal air 
and metabolites in urine (Adibi et al. 2008). Although the personal air results presented here are on 
a larger sample (168 versus 96 women), the distributions of DEP, DnBP, MEP, and MnBP are 
entirely consistent with our previous results which showed that on average concentrations of MEP 
were similar in this population to those in NHANES (females 18-40 years of age in the 1999-2000 
& 2001-2002 NHANES) but that participants in the CCCEH had higher urinary concentrations of 
MnBP (Adibi et al. 2008). Our understanding of the previously reported correlation between 
personal air DEP and urinary concentrations of MEP is enhanced by stratifying by the use of 
perfume. Among non-perfume users there is a higher correlation than we have previously reported 
and among perfume users there is no apparent association between DEP and MEP.  
Our questionnaire covered only a subset of potential products used in the home which 
might contain phthalates. Use of products in these categories could be indicative of a preference for 
products containing fragrance and perhaps use of other phthalate-containing products as well, such 
as air fresheners or cleaning products. In addition, our questionnaire did not include the amount of 
products used which can vary substantially; one study, for example, found an 18-fold range in the 
average mass of spray perfume used per day among regular female users over a two week period 
(Loretz et al. 2006). Individuals also vary in their uptake of phthalates after exposure, in 
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metabolism of the parent compound into the urinary metabolites, and in the timing of their urine 
sample relative to product use. We would expect additional contributors to this type of variability 
among pregnant women due to differences in gestational age at the time of sampling, blood 
volume, and renal and placental function (Adibi et al. 2008). All of these unmeasured factors 
contribute to variability and the limited explanatory power of the models presented here. While the 
multivariable regression model presented in Table 3 explained 19% of the variability in urinary 
MEP, the R2 from a univariate model of perfume use (yes/no) alone, while highly significant, only 
explained 11% of the variance in the specific gravity adjusted and log transformed urinary 
concentrations of MEP. Both our multivariable and univariate regression models explained ≤ 5% 
of the variance in DnBP or MnBP. 
In conclusion, we report that pregnant women in this urban cohort used multiple personal 
care products and that the use of perfume was positively associated with urinary concentrations of 
MEP, a surrogate measure of exposure to DEP. It is important to assess if there are adverse effects 
of human exposures during critical periods given the heightened exposure to DEP associated with 
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Background and Aims: Phthalate plasticizers are found in consumer products and home furnishing 
materials but their contribution to personal exposure remains unclear. Previous studies have shown 
associations between vinyl flooring and plastic wall coverings and house dust concentrations of 
both butylbenzyl phthalate (BBzP) and di(2-ethylhexyl) phthalate (DEHP), however total exposure 
to the latter is believed to be primarily dietary. We hypothesized that children living in homes with 
vinyl flooring would have higher concentrations of BBzP in their home indoor air and higher 
concentrations of monobenzyl phthalate (MBzP, a BBzP metabolite) in their urine than other 
children. 
Methods: BBzP and DEHP exposures were examined in an ongoing prospective cohort of New 
York City children 5-10.6 years old (n=220) using: (1) a checklist for the presence of potential 
phthalate containing materials in the home (including “vinyl or linoleum flooring”); (2) a two-
week home indoor air sample collecting particle and gas phase phthalates at 1.5 LPM at the child’s 
breathing height; and (3) urinary metabolites analyzed in a spot sample (n=176 collected during air 
sampling). 
Results: The category “vinyl or linoleum” flooring was observed in 125 (57%) of the homes. 
Homes with vinyl or linoleum flooring had a significantly higher concentration of BBzP 
(Geometric mean (GM) 24.3; interquartile range [IQR] [9.3, 66.8] ng/m3), than those with wood or 
carpet flooring (GM 10.9; IQR [6.9, 14.1] ng/m3, n=95) (Mann-Whitney test, p<0.001) and 
accounted for the 16 highest concentrations of indoor air BBzP and 88% of the highest quintile 
(n=39/44). The concentration of BBzP in the two-week air sample was correlated positively with 
urinary MBzP concentration (Spearman’s rho 0.41, p<0.001). MBzP also was higher among 
children from homes with “vinyl or linoleum” versus other types of flooring (Mann-Whitney test, 
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p<0.001). There was no difference in DEHP by flooring type (p=0.93), no correlation of DEHP 
with its urinary metabolite mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) (rho=0.04, 
p=0.57), and no difference in MEHHP by flooring type (p=0.67). 
Conclusions: Home materials, particularly vinyl flooring, may be an important source of exposure 







The phthalates are a set of related compounds with widespread commercial uses (Schettler 
2006). Different phthalates have different physical and chemical properties that contribute to 
variations in uses and patterns of human exposure. While the lower molecular weight phthalates 
are used in personal care products, two of the higher molecular weight phthalates, butylbenzyl 
phthalate (BBzP) and di(2-ethylhexyl) phthalate (DEHP) are added to plastics to give them 
flexibility and since they are not chemically bound, they can leach out of these materials and 
contaminate food, dust, and indoor air. BBzP is used primarily in the production of vinyl tiles as 
well as in some adhesives, carpet tiles, food conveyor belts, and artificial leather [National 
Toxicology Program-Center for the Evaluation of Risks to Human Reproduction (NTP-CERHR) 
2003]. DEHP is primarily used as a plasticizer in flexible polyvinyl chloride (PVC) plastics and in 
consumer products such as flooring, car upholstery, food packaging, some toys, and medical 
devices (NTP-CERHR 2006). Although BBzP and DEHP have low volatility due to their high 
molecular weight, both are adsorbed onto respirable particles (Rakkestad et al. 2007) and 
considerable quantities have been found in studies collecting semi-volatile and particle bound 
phthalates together in personal and indoor air samples in Massachusetts, California, and New York 
City (Adibi et al. 2008; Rudel et al. 2003; Rudel et al. 2010).  
Urinary concentrations of phthalate monoester metabolites are considered the best available 
biomarkers of exposure because they integrate total exposure and are not subject to contamination 
by plastics in sample processing and analysis (Hauser and Calafat 2005). Previous studies have 
found phthalate metabolites in virtually all tested samples from pregnant women, children, and in 
the U.S. representative NHANES (Adibi et al. 2008; Silva et al. 2004; Teitelbaum et al. 2008). 
While biomarker measures indicate ubiquitous exposure, concentrations of phthalate metabolites 
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can vary over orders of magnitude, likely due to different patterns of exposure, uptake, and/or 
metabolism across the population.  
Controlled dosing studies in adults indicate that variability in metabolism and excretion 
dynamics of phthalates are substantially less than the total variability in biomarker measures, 
although the applicability of these results to children is unclear. In a controlled dosing study with 
seven adults, 73% of an ingested dose of isotope-labeled BBzP was excreted in urine as the 
monoester metabolite monobenzyl phthalate (MBzP) with a relative standard deviation between 
individuals of 39% and 26% for low and high doses (Anderson et al. 2001). In contrast to BBzP, 
DEHP metabolites undergo a further oxidation stage after hydrolysis to the monoester. The 
resulting secondary oxidative metabolites are considered better biomarkers because they are more 
frequently detected and have longer biologic half-lives than the monoester (Koch et al. 2006; Preau 
et al. 2010). In a more recent study, four DEHP metabolites were measured in urine collected over 
regular intervals up to 48 hours after 10 male and female adults (ages 18-77) were given labeled 
doses of DEHP (Anderson et al. 2011). Over 48 hours, 6% of the dose was excreted in urine as the 
monoester metabolite mono(2-ethylhexyl) phthalate (MEHP) with a relative standard deviation of 
31%. The oxidative metabolite mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) made up the 
largest share with 16% of the dose and a relative standard deviation of 20%. DEHP metabolites 
were estimated to have a half-life of 4-8 hours with greater than 90% excretion in the first 24 
hours.  
In this study, we hypothesized that vinyl flooring in the home would be associated with 
higher indoor air concentrations of BBzP and higher urinary concentrations of MBzP among 
children. We also tested whether the same relationships would hold for DEHP, a ubiquitous 
phthalate used in PVC plastics for which children’s exposure is believed to be primarily dietary 
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(Wormuth et al. 2006). For DEHP, we hypothesized that vinyl flooring in the home would be 




Cohort design and enrollment 
Participants for this study were children in the Columbia Center for Children’s 
Environmental Health (CCCEH) longitudinal birth cohort study (Perera et al. 2003; Whyatt et al. 
2003). A total of 727 women were enrolled into the cohort during pregnancy between 1998-2006 
from prenatal clinics at two hospitals in Northern Manhattan. Eligible participants included non-
smoking pregnant self-identified Dominican or African American women ages 18-35 who reported 
living within Northern Manhattan or the South Bronx for ≥ 1 year and detailed exclusion criteria 
have been previously reported (Perera et al. 2003). The study was approved by the Institutional 
Review Board of Columbia University Medical Center and all participants signed an informed 
consent prior to enrollment. For this study, a subset of n=220 children were selected who had 
reached the age of 5 years and had available data from a checklist of materials that might contain 
phthalates in the home, and collection of an indoor air and child’s spot urine sample. The spot 
urine was collected during indoor air sampling for n=176 participants. Both analytic laboratories 






Child’s race/ethnicity, mother’s education, and marital status were based on maternal self-
report. A checklist for the presence of materials in the home that are likely to contain phthalates 
was administered by field staff at the time of the indoor air sampling (see Appendix to Chapter 4). 
The checklist was completed in the same room as the air sampling (usually the child’s room) as 
well as several others in the home. It included observation of the type of flooring, plastic coverings 
on furniture, plastic blinds or window treatments, and plastic shower curtains. Flooring was 
categorized as one of “vinyl or linoleum”, wood, carpet, ceramic tile, or other. The category of 
“vinyl and linoleum” flooring combined these floor types in the checklist based on prior work that 
these materials are not easily distinguishable by visual inspection, although phthalates are added to 
vinyl and not linoleum flooring products (Kolarik et al. 2008). Since there were only three homes 
with ceramic tile and none with “other” flooring in the room that was monitored these categories 
were dropped from all analyses, with n=220 homes remaining with wood, carpet, or “vinyl or 
linoleum” in the monitored room. 
 
Indoor air 
Two-week integrated air samples, which collected respirable particles and semi-volatiles, 
were used to characterize total airborne concentrations of phthalates occurring in the home 
environment. Stationary air monitors were set up preferentially in the child’s bedroom or main 
living space to sample continuously at 1.5 l/min and ran for 13 to 16 days (92% of samples were 
14 days). Samplers used a PM2.5 cyclone (BGI, Waltham, MA) with a quartz filter followed by a 
polyurethane foam plug (PUF) encased in a modified URG personal pesticide sampler (University 
Research Glassware, Chapel Hill, NC). After collection, PUFs and filters were stored at -20°C 
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before shipment on dry ice to Southwest Research Institute in San Antonio, TX where they were 
extracted together before analysis with GC/MS using isotope-labeled internal standards (Adibi et 
al. 2008). Laboratory matrix blanks were extracted and analyzed with each batch of samples. 
Although there was evidence of sporadic contamination in the laboratory, the geometric mean 
concentration in matrix blanks (GM 39 ng BBzP per extract, 95% CI 36 to 42 ng per extract; GM 
121 ng DEHP per extract, 95% CI 99 to 148 ng per extract, n=102) was considerably lower than 
among extracts from two-week indoor air samples (GM 522 ng BBzP per extract, 95% CI 452 to 
603 ng per extract; GM 2706 ng DEHP per extract, 95% CI 2529 to 2896 ng per extract). 
 
Urine measures  
Of the 176/220 (80%) of children with spot urines collected during the two-week air 
sampling, 24% were collected on the first day and 48% on the last day of sampling with the 
remaining samples collected at clinic visits which were largely afterschool. The 44 urine samples 
collected outside the period of the two-week air sampling ranged from 97 days before to 47 days 
after air sampling. These were used primarily to explore the sensitivity of the correlation between 
air and urine measures to temporal concurrency. Samples were stored at -80°C until shipment on 
dry ice to the Centers for Disease Control and Prevention laboratory for analysis. Measurements 
used isotope-labeled internal standards with high performance liquid chromatography and tandem 
mass spectrometry (Adibi et al. 2008; Silva et al. 2007). Studies utilizing repeated samples have 
shown that phthalate urinary metabolite concentrations are likely stable after long-term frozen 
storage (Baird et al. 2010; Samandar et al. 2009), and concentrations from a single spot urine 
sample are reasonably representative of concentrations over several months in pregnant women in 
this cohort (Adibi et al. 2008). In another study of New York City children, MBzP concentrations 
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were more reproducible than metabolites of DEHP (Teitelbaum et al. 2008). Overall, fewer studies 
have analyzed exposure to phthalates in early school-aged children than adults because of the 
additional difficulty in enrollment and sample collection.  
 
Statistical analysis 
Because concentrations of air phthalates were non-normally distributed, we used non-
parametric tests: Mann-Whitney tests for independent samples, and Spearman’s rho for rank 
correlations. Concentrations of urinary metabolites were approximately log-normally distributed 
and were natural log transformed prior to analysis. Analyses were conducted using R version 
2.13.1 with the beanplot and ggplot2 packages for graphics (Kampstra 2008; R Development Core 
Team 2011; Wickham 2009). 
 
Results 
The 220 children enrolled ranged in age from 5.0 to 10.7 years (mean 6.6 years, 90% less 
than 9 years) and included more Dominican than African American children (Table 1). The 
category “vinyl or linoleum” was the most frequently observed flooring in 57% (n=125/220) of the 
rooms monitored. Wood was the next most frequent category (32%, n=71/220), followed by carpet 
(11%, n=24/220). There was no association between flooring type and mother’s race/ethnicity, 




Table 1. Characteristics of (n=220) children and mothers 
Child's Age (years) mean (SD) 6.6 (1.7) 
Child's Sex (% male) 48 
Ethnicity 
     African American (%) 33 
     Dominican (%) 67 
Mother’s Education 
     High school or greater (%) 69 
Mother’s Marital Status 
     Never married (%) 65 
Missing: mother’s marital status (n=1) 
 
 
Phthalates were detected in all air samples and urinary metabolites were detected in all 
urine samples. Distributional summary statistics for the concentrations of phthalates in two-week 
indoor air samples and urinary metabolites from children’s spot urines are shown in Table 2. The 
concentrations of BBzP in indoor air were overall lower than those of DEHP (p<0.001). There was 
no difference in metabolite concentrations in urine samples collected during versus not during the 
air sampling (not shown). 
 








> LODa Min 25% 50% 75% 95% Max GM (95% CI) 
(ng/m3) 
         BBzP 
 
100% 2 8 13 32 186 353 17 (15 to 20) 
DEHP 
 
100% 28 61 82 122 241 353 89 (83 to 95) 
 (ng/ml) 
         MBzP 100% 1 17 35 76 235 1950 36 (31 to 42) 
 MEHP 90% <LOD 2 5 11 39 333 5 (4 to 6) 
 MEHHP 100% 2 24 54 115 326 1690 52 (45 to 61) 
LOD, limit of detection; GM, geometric mean 
an=37 air samples were below the lowest standard for BBzP leading to imprecise quantitation; 
n=21 samples were below the LOD for MEHP, which was in the low ng/ml range, and these 





As can be seen in Figure 1, there was no significant difference between BBzP 
concentrations measured in rooms with carpet versus wood flooring (p=0.27). Rooms with “vinyl 
or linoleum” flooring had a significantly higher concentration of BBzP (GM 24.3; IQR [9.3, 66.8] 
ng/m3), than homes with wood or carpet flooring (GM 10.9; IQR [6.9, 14.1] ng/m3, n=95) 
(p<0.001). The homes with “vinyl or linoleum” flooring in the room being monitored accounted 
for the 16 highest concentrations of indoor air BBzP and 88% of the highest quintile (n=39/44). 
However, they also spanned the range of the exposure distribution for the three types of flooring 
(2.4 to 353 ng/m3 BBzP). As shown in Figure 1, there was no difference in the distribution of 
indoor air DEHP by flooring type (p=0.93). A separate question that characterized the total 
proportion of the flooring of the home that was “vinyl or linoleum” found marginal associations for 
a higher distribution of BBzP in homes with more than half of the home having “vinyl or 
linoleum” flooring after stratifying by the flooring in the room being monitored (Figure 2). Further, 
the flooring in the monitored room was associated with the categorization of the total flooring in 
the home. There were only seven homes with carpet or wood in the monitored room that had 
greater than 50% total “vinyl or linoleum” flooring and only ten homes with “vinyl or linoleum” 





Figure 1: Beanplots show the distribution of BBzP and DEHP concentrations in two-week 
indoor air samples by type of floor in the room being monitored (n=220).  
There was no difference in BBzP between carpet and wood (p=0.27) although those two groups 
together were substantially lower than “vinyl or linoleum” (p<0.001). The 16 highest values were 
in the “vinyl or linoleum category”, which made up 39/44 homes in the top quintile greater than 40 
ng/m3. There was no difference between “vinyl or linoleum” and the combination of carpet and 
wood for DEHP (p=0.93). Each horizontal dash is one home with group geometric means shown 
as darker black lines and dotted grand geometric means for each phthalate. The shape of the ‘bean’ 





Figure 2: Distribution of concentrations of BBzP in two-week indoor air samples and 
whether half or more of the total home has “vinyl or linoleum” flooring, stratified by floor 
type in the room with the monitor.  
The small sample sizes in the discordant cells indicate that the flooring in the room being 
monitored was representative of the home. Nonetheless, these associations were suggestive that the 
flooring in the remainder of the home contributed to the indoor air concentration measured in a 
single room (p=0.07 and p=0.09). 
 
 
Indoor air concentrations of BBzP and DEHP were correlated in homes with carpet or 
wood flooring in the monitored room (rho=0.33, p=0.001, n=95), but not in homes with “vinyl or 
linoleum” flooring (rho=0.03, p=0.72, n=125) (Figure 3). Among the homes with “vinyl or 
linoleum” flooring, a subset had indoor air concentrations of BBzP that exceeded the indoor air 





Figure 3: Association between indoor air concentrations of DEHP and BBzP stratified by 
floor type.  
There is a correlation between indoor air DEHP and BBzP concentration only among those with 
carpet or wood (rho = 0.33, p = 0.001, n = 95) and not vinyl or linoleum flooring (rho = 0.03, p = 




The concentration of BBzP in the two-week air sample was correlated positively with 
concurrent urinary MBzP concentration (rho=0.41, p<0.001, n=176); a similar correlation was seen 
in a subset of urine samples collected five or more days before or after the air sampling (n=20, 
median 13 days apart, rho=0.37, p=0.11). The concentration of DEHP was not correlated with 
concurrent MEHP (rho=0.02, p=0.75), or MEHHP (rho=0.04, p=0.57). 
The distributions of urinary metabolite concentrations by floor type are shown in Figure 4. 
Urinary MBzP concentrations were also higher among children with “vinyl or linoleum” in the 
monitored room versus the combination of carpet or wood (p<0.001). As in the air monitoring, 
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there was no difference in the distribution of urinary MBzP concentration between the carpet and 
wood (p=0.83). There was no difference in the distribution of urinary MEHHP concentrations 
between children with “vinyl or linoleum” in the room monitored versus the combination of carpet 
and wood (p=0.67).  
 
 
Figure 4. Beanplots show the distribution of urinary concentrations of MBzP and MEHHP in 
spot urine collected during the air sampling by type of floor in the room being monitored 
(n=176).  
There was no difference in MBzP concentration between carpet and wood (p=0.83), and these two 
categories together was significantly lower than “vinyl or linoleum” (p<0.001). There was no 
difference between “vinyl or linoleum” and the other two categories for MEHHP (p=0.67). Each 
horizontal dash is one home with group geometric means shown as darker black lines and dotted 
grand geometric means for each phthalate. The shape of the ‘bean’ gives the weight of the 





This study is consistent with previous findings in both Sweden and Bulgaria that vinyl 
flooring is an important predictor of concentrations of BBzP in home air and dust (Bergh et al. 
2011; Bornehag et al. 2005; Kolarik et al. 2008). The addition of biomonitoring data in this study 
also demonstrates that home flooring may be an important source of internal exposure to BBzP 
among children. Further, the correlation in the current study between BBzP and MBzP 
concentrations in air and urine supports previous findings that the indoor environment may be an 
important source of exposure for this phthalate via inhalation, dermal absorption, or incidental 
ingestion. The correlations seen here were similar but somewhat lower than seen previously in a 
study that measured BBzP in maternal 48-hour personal air and spot urine samples (rho=0.48, 
p<0.05, n=62) (Adibi et al. 2008). This lower correlation may be due to a larger mismatch in the 
duration of the air monitoring versus the short biologic half-life of hours for the urinary metabolite, 
or to the contribution of BBzP in air from other micro-environments outside the home that was 
captured by backpack monitoring in the previous study. However, repeated sampling of both BBzP 
in two-week indoor air and urinary MBzP in maternal spot urines have previously shown good 
reproducibility in 2-4 samples collected over 6-8 weeks (ICC 0.83, n=32 for BBzP; ICC 0.66, 
n=28 for MBzP). The lack of a correlation between concentrations of DEHP in the indoor air 
samples and metabolites in urine samples is also consistent with the prior study of personal air and 
urine concentrations seen in the mothers in the current cohort (Adibi et al. 2008), as well as a 
German study measuring DEHP in sieved vacuum cleaner bag dust and spot urine samples in 
n=254 children aged 3 to 14 (Becker et al. 2004). Consistent with these results, a European 
exposure model using scenario-based probabilistic source apportionment calculated that indoor air 
contributes 26% of children’s exposure to BBzP with diet contributing 73% of exposure. By 
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contrast, diet was estimated to contribute >90% of children’s exposure to DEHP, with inhalation 
from indoor air making up the remainder (Wormuth et al. 2006). 
Although these results support vinyl flooring as an important source of BBzP, substantial 
concentrations were still measured in the indoor air of homes with no observable vinyl flooring. 
We speculate that shared sources of both BBzP and DEHP such as consumer products containing 
plasticizers, or else a shared reservoir in house dust may explain the correlation of BBzP and 
DEHP concentrations in homes without vinyl flooring. 
We also observed considerable variability in the indoor air concentrations of BBzP among 
homes with “vinyl or linoleum”, in the room that was monitored. Some of this may be attributable 
to homes using linoleum flooring, which would contain no plasticizers. The distribution of BBzP 
concentrations among homes with “vinyl or linoleum” flooring remained skewed after log 
transformation and had an appearance that would be consistent with a mixture of a log-normal 
distribution similar to those in the carpet or wood floor homes and a second distribution that was 
higher and more variable. There was also no information available on the composition, brand, age, 
or condition of the flooring, particularly the presence of water damage, which are likely to be 
important parameters in explaining the contribution of flooring to indoor air phthalate 
concentrations. Most of the homes monitored in this study had little variability in flooring type 
within the major rooms of the home. Although the category of “vinyl or linoleum” flooring was 
quite common in this population, we do not know if the types of materials used in housing in New 
York City would be representative of those in other areas.  
In this study, the presence of particular flooring materials, a combination of vinyl or 
linoleum, was a sensitive but non-specific factor accounting for nearly every home in the highest 
range of indoor air concentration of BBzP. The correlation of BBzP and urinary MBzP, and the 
66 
 
association of flooring with metabolite concentrations further supports the indoor environment as a 
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Background: Our prior analyses showed that concentrations of four metabolites of di(2-
ethylhexyl) phthalate (DEHP) measured in prenatal spot urines were individually and as a molar 
sum associated with shortened gestation in an inner-city pregnancy cohort. The high 
multicollinearity of the phthalate metabolites poses a challenge in modeling multiple exposures 
simultaneously. Bayesian methods, which can stabilize estimation and incorporate prior knowledge 
have not been widely applied to biomonitoring data. The current study is the first application of 
Bayesian regression models to assess associations between highly correlated biomarkers and a 
continuous outcome.  
Methods: We compare models that fit one phthalate metabolite at a time with a full multiple linear 
model and with the following Bayesian models: model 1 equivalent to ridge regression, and model 
2 a simple hierarchical Bayes model that groups regression coefficients of similar predictors. We 
assess whether Bayesian methods improve parameter estimation of the association between urinary 
concentrations of multiple phthalate metabolites and gestational age. Sensitivity analysis was 
performed to allow various prior distributions of exposure effects. 
Results: Parameter estimates from Bayesian models are more stable with smaller variance 
estimates compared with those from the multiple linear model for highly correlated exposures. No 
single phthalate metabolite is significantly associated with gestational age, although three have 
relatively large negative effect estimates: mono(3-carboxypropyl) phthalate, a metabolite of high 
molecular weight phthalates including di-n-octyl phthalate and two DEHP metabolites, mono(2-
ethylhexyl) phthalate and mono(2-ethyl-5-hydroxyhexyl) phthalate. 
Conclusions: Several phthalate metabolites appear together to be associated with reduced 




Phthalates are plasticizers commonly used in household and consumer products to confer 
flexibility (Schettler 2006). Exposure to mixtures is common with metabolites of a number of 
phthalate metabolites detected in 100% of urine samples (Adibi et al. 2008). These concentrations 
are often highly correlated both because some metabolites share common parent compounds and 
because phthalates can have similar sources of exposure. Preliminary epidemiology has shown 
associations between a number of phthalates and male urogenital development, neurodevelopment, 
asthma, and modulation of the length of gestational age (Bornehag and Nanberg 2010; Engel et al. 
2009; Swan 2008; Whyatt et al. 2009). Thus, the phthalates (and their metabolites) represent one 
example of a common mixture of environmental contaminants for which appropriate 
epidemiologic models are needed in order to estimate the association with health outcomes of 
interest, a recommendation of a recent report on cumulative assessment of the phthalates by the 
National Academies (Committee on the Health Risks of Phthalates 2008). 
Several data analytic techniques have been used previously for estimating associations of 
concentrations of multiple phthalate metabolites with health outcomes. These include conventional 
strategies for handling multiple (correlated) variables in regression analyses: analyzing one 
metabolite concentration at a time using multiple models (Whyatt et al. 2009), pretesting for 
statistical significance in order to select subsets of phthalates (Swan et al. 2005), and construction 
of summary scores with fixed component weightings (Engel et al. 2009). Because exposures occur 
simultaneously, models that estimate associations of components of mixtures with health outcomes 
one at a time as though each were the only relevant environmental predictor fail to take into 
account potential confounding effects from other environmental exposures and can lead to biased 
effect estimation. By contrast, ordinary least squares (OLS) estimates of regression coefficients in a 
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multiple linear model could be unstable with all the highly correlated environmental exposures in 
the same model. This phenomenon is called multicollinearity in a multiple regression. A more 
desirable statistical technique, such as a Bayesian regression model, would take into account all of 
the relevant exposures and offer insight into the relative importance of the mixture components 
(Greenland 1994). Bayesian regression models extend multiple linear regression models by 
treating the exposure effects as random variables, which can depend on second level covariates 
through some prespecified distributions. The principal purpose of the current study was to compare 
four statistical modeling approaches for highly correlated biomarkers: two regular linear regression 
models and two Bayesian models. Our goal is to provide some regression techniques that produce 
stable and reasonable regression estimates of the association of multiple correlated exposure 
biomarkers with a continuous health outcome.  
 
Bayesian Models 
We consider the following Bayesian regression model without intercept, in which the 













2,~| σββ  
                                               
 
β j ~ N µ,τ
2( ).                                        (1) 
Where, pββ ,,1   are effect measures for exposures pxx ,,1  . In contrast to estimates from a 
linear regression model fit using OLS, in model (1) the parameter estimates pββ ,,1  are treated as 
random and follow a prior normal distribution with mean, µ, and variance τ2. The estimates of 
pββ ,,1   obtained though model (1) are moved away from the OLS estimates and toward 
 
µ , the 
center of the prior distribution. This procedure, which adds a small amount of bias to parameter 
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estimates but reduces variance estimates, is known as shrinkage. This bias-variance tradeoff often 
results in estimates with smaller mean squared errors (the combined effect of bias and variance) 
than the OLS estimates, especially in the presence of multicollinearity. 
 When μ = 0, Model (1) is equivalent to a ridge regression model with a penalty term for 
shrinkage, where the shrinkage parameter 22 τσλ = . Ridge regression is one of several methods 
that have been proposed to remedy the problem of predictor multicollinearity (Hastie et al. 2009). 
Ridge regression is fit by statistical packages via matrix operations as a penalized regression model 
(Venables and Ripley 2002). The shrinkage parameter λ determines how much the regression 
estimates move away from the maximum likelihood estimate and toward zero. Specifically, when λ 
= 0, it is equivalent to an ordinary linear regression; and when λ = infinity, it is an intercept only 
model with all regression coefficients forced to 0. The shrinkage parameter can be chosen so as to 
minimize the estimated prediction errors via generalized cross-validation (Golub et al. 1979; Hastie 
et al. 2009). 
An important assumption in the ridge equivalent Bayesian model is exchangeability of the 
exposure effects which are put under a common prior distribution, meaning that the data analyst 
believes that the magnitude of associations from various predictors likely come from the same 
prespecified probability distribution. If previous evidence exists that predictors can be categorized 
into groups, where the effects of predictors are more similar within groups than between groups, 
the Bayesian model can be restructured to incorporate this grouping (Momoli et al. 2010). This 
grouping can be achieved by allowing β  in model (1) to depend on the effects of a group indicator 
and its prior mean. Model (1) can be rewritten as, 
 























  , 
 
γ g ~ N µg ,φg
2( ) ,                        
                                   
 
τ 2 ~ IG α1,α2( ), 
 
σ ~ Uniform(0,103),                              (2) 
where exposures are clustered into G groups and 
 
zgj  is group indicator for the 
 
j th  exposure. The 
effect of belonging to the 
 
gth  group is 
 
γ g , whose prior mean, 
 
µg , is the prior knowledge regarding 
the size of 
 
γ g , and the prior variance, 
 
φg
2, represents uncertainty about that effect size. Unlike the 
fixed shrinkage in model (1), model (2) allows for adaptive shrinkage and makes estimates more 
data driven (MacLehose et al. 2007). This grouped hierarchical Bayes model (2) also relaxes the 
global exchangeability of the exposure effects and thus improves model fit and reduces mean 
squared errors. Annotated statistical code for use with R and WinBUGS to allow investigators to 




As explained in detail elsewhere (Whyatt et al. 2009), participants were pregnant African 
American and Dominican women with prenatal urine specimens available for analysis and medical 
record data from the Columbia Center for Children’s Environmental Health study of Mothers and 
Newborns (Perera et al. 2003). All participants signed consent, approved by the IRB of Columbia 
University, at the time of study enrollment. Our selection criteria of study subjects were similar to 
our prior analyses of the association between prenatal concentrations of DEHP metabolites and 
gestational age, with the following modifications. In our previous analysis we controlled for the 
subsequent report of active smoking during pregnancy, however, here we excluded 10 such 
individuals because active smoking was an exclusion criterion at enrollment for the cohort. Due to 
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the selection of a smaller set of other covariates not previously shown to act as confounders 
(Whyatt et al. 2009), the sample size of participants with complete data was 249, of these 233 were 
also in the fully adjusted model of our prior analysis. 
 
Phthalate measurement 
A spot urine was collected during the third trimester of pregnancy. Specific gravity was 
measured with a handheld refractometer at room temperature, and a total of eight urinary phthalate 
metabolites, listed in Table 1 with their parent compounds, were measured at the Centers for 
Disease Control and Prevention (Kato et al. 2005). Details on the prenatal exposure to phthalates in 
this cohort have been published elsewhere (Adibi et al. 2008; Just et al. 2010; Whyatt et al. 2009). 
Several phthalate metabolites whose concentrations were not available for the entire cohort 
(monomethyl phthalate, monocarboxy-isooctyl phthlate, and monocarboxy-isononyl phthlate) were 
excluded from further analysis. Samples with concentrations that were below the limits of 
detection, which were in the low nanogram per milliliter range for all metabolites, were imputed 
with a value equal to ½ the limit of detection. 
 
Gestational age and predictors of interest 
Gestational age at delivery, measured in weeks, was extracted from medical records 
(Whyatt et al. 2009). In our previous analysis, we examined many potential confounders and 
reported adjusted effect size estimates primarily to increase model precision rather than because of 
evidence of confounding (Whyatt et al. 2009). In the current analysis, we included two potential 
confounders that were previously statistically significant predictors of gestational age in this 
dataset, planned Cesarean section, and premature rupture of membranes, which were both yes/no 
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variables. However, it should be noted that our previously reported associations between urinary 
concentrations of DEHP metabolites and gestational age were unchanged in the reduced linear 
regression models with this slightly different set of participants (Whyatt et al. 2009). 
Because of the extreme correlation between the urinary concentrations of two of the 
secondary oxidative metabolites of DEHP, mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) 
and mono(2-ethyl-5-oxohexyl) phthalate (MEOHP) (r = 0.98) which is presented below in results, 
and because MEHHP concentrations had a stronger association with gestational age than MEOHP 
concentrations when tested individually, we removed MEOHP concentrations from our regression 
modeling. 
 Urinary metabolite concentrations were adjusted for dilution relative to the median 
specific gravity among this cohort of pregnant women, a modification of the method of Hauser and 
colleagues (Hauser et al. 2004; Just et al. 2010). Phthalate metabolite concentrations were 
subsequently log transformed as their concentrations, like many other exposure biomarkers, are 
right skewed. As shrinkage estimation techniques are not scale invariant, we standardized our 
regression predictors, including both continuous and binary variables, by subtracting the mean and 
dividing by the standard deviation to put them all on a common scale of standard deviation units.  
 
Modeling strategies 
We used penalized splines to check for non-linear associations between individual 
phthalate metabolites and gestational age (details in Appendix 1). Since our results showed an 
inverse association consistent with linearity, we used our predictors as linear terms in our 
regression models. We report the results from four modeling approaches using an expanded set of 
phthalate metabolites relative to our previous analysis. All of the models were fit without an 
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intercept using a centered outcome by subtracting the mean gestational age from each record 
before regression (mean 39.3 weeks, range 34 to 42 weeks). The two conventional model fitting 
strategies were to model each of the eight metabolites concentrations one at a time (“Single 
Models”) and to model the effects of all metabolites concentrations together in a multiple linear 
regression model using OLS (“Full OLS”). Both model strategies adjusted for the effects of the 
other two covariates: planned Cesarean section and premature rupture of membranes. 
In addition, we fit two Bayesian models. The first was a simple Bayesian model equivalent 
to ridge regression on the multiple regression model (“Bayes-Ridge”). The second Bayesian model 
as shown in Model (2), also fit with the full set of predictors, added some flexibility by allowing 
the prior means of the exposure effects to vary in different groups of similar predictors (“Bayes-
Group”). The selection of predictor variables into groups in the second Bayesian model was based 
on the belief that concentrations of DEHP metabolites were more likely to have similar effects 
sizes than the metabolites of other phthalates or the other (non-phthalate) covariates. The three 
groups were non-DEHP metabolites (5 predictors), DEHP metabolites (3 predictors), and other 
covariates (2 predictors). Prior means of effect measures were centered at zero, and prior variances 
were selected to correspond to the penalization term that minimized prediction error in ridge 
regression based on a generalized cross-validation statistic. This selection of the prior parameters 
and a sensitivity analysis using different values for this prior variance are both discussed further in 
our Appendix 2. 
R (version 2.12.2) and WinBUGS (version 1.4.3) were the primary statistical systems used 
(Lunn et al. 2000; R Development Core Team 2011). The R package “R2WinBUGS” was used to 
call WinBUGS and export results into R (Sturtz et al. 2005). Graphics were created in R using the 





The distributions of phthalate metabolite concentrations (before adjustment with specific 
gravity) are presented in Table 2. The correlations between concentrations of phthalate metabolites 
were all positive and ranged from 0.07 to 0.98 and are shown in Table 3. Concentrations of 
metabolites from the same parent compound (such as MEHP and MEHHP, r = 0.84) are more 
highly correlated than metabolites from different parent compounds (such as MiBP and MBzP, r = 
0.41). All of the scatterplots that show patterns of correlation appear to have a linear relation after 
logarithmic transformations. 
We used four different modeling strategies with the concentrations of eight target phthalate 
metabolites and the two other covariates (premature rupture of membranes and planned Cesarean 
section). The resulting coefficient estimates for standardized predictors from these four modeling 




Figure 1. Comparison of coefficient estimates and 95% confidence/credible intervals from 
four modeling strategies.  
Single models (one phthalate + 2 covariates in each model), a full model with all predictors fit with 
ordinary least squares linear regression (Full-OLS), a Bayes–Ridge full model, and a Bayes–
Groups full model with grouping of similar predictors. Magnitude represents change for a one 
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standard deviation change in predictor on the mean gestational age in an urban cohort (n = 249). 
Phthalate metabolite concentrations are adjusted for specific gravity and log transformed prior to 
standardization. Because the two other covariates were included in each of the 8 single models, 
their many estimates are not shown. 
 
Parameter estimates for non-DEHP metabolites were close to zero in all models, except for 
MCPP although the 95% credible interval for this parameter estimate still spanned no effect in both 
Bayesian models.  
In single models, concentrations of the three DEHP metabolites are negatively associated 
with gestational age with very similar parameter estimates (-0.19, -0.14, and -0.20 change in weeks 
of gestational age for a one standard deviation change in log adjusted metabolite concentration for 
MEHP, MECPP, and MEHHP respectively). However, the parameter estimates for these 
metabolites were highly unstable in the Full OLS model. This is best demonstrated by the large and 
opposite estimates and wide 95% confidence intervals for MECPP and MEHHP, despite their 
pairwise correlation being as high as 0.93. By contrast, DEHP metabolites in both Bayes models 
have more reasonable parameter estimates with smaller variances. The sum of the parameter 
estimates from the three DEHP metabolites (MEHP + MECPP + MEHHP) in the Bayes models (-
0.17 for Bayes-Ridge and -0.20 for Bayes-Group) is similar to the range of parameter estimates for 
each of these three DEHP metabolite in the corresponding single models. Both Bayesian modeling 
strategies indicate that MCPP, MEHP, and MEHHP might be most important because they have 
the largest (negative) magnitude in their parameter estimates but none of these individually achieve 
statistical significance. 
Both the Bayes-Ridge and Bayes-Group models reduce the variance with more narrow 
95% CIs for phthalate parameter estimates compared with the conventionally fit Full OLS model. 
In addition, in the Bayes-Group model the estimates for the two other covariates, premature rupture 
of the membranes and planned Cesarean section, retain larger magnitudes (more negative) 
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compared with the Bayes-Ridge model and are more similar to their estimates in the Full OLS 
model. It is worth emphasizing that these two other covariates are quite different in interpretation 
and distributional properties from the phthalate exposures. Although their inclusion in the model 
did not substantially alter effect size estimates making them not appear to be confounders by 
criteria of collapsibility (data not shown), they were better predictors than the phthalate 
metabolites. A linear regression model with premature rupture of the membranes and planned 
Cesarean section had an adjusted R2 of 0.10 while the addition of the single metabolite with the 
strongest association, MEHHP, only increased the adjusted R2 to 0.12. 
A sensitivity analysis that used different values for the prior variance (multiplying by ½ or 
by 2) as well as modifying the structure of the data level and group-level error terms did not 
substantially vary our findings. Further discussion can be found in our Appendix 2. 
 
Discussion 
Consistent with our prior analysis, we observe a linear decrease in gestational age 
associated with urinary concentrations of metabolites of DEHP modeled one at a time. However, 
our analysis suggests that results from a series of single models can be misleading when predictors 
are highly correlated. We used three groups of predictors: five non-DEHP metabolites 
concentrations, three DEHP metabolites concentrations, and two other covariates. The 
concentrations of non-DEHP metabolites are correlated but not as highly as the DEHP metabolites 
that share a common parent compound. Because most of the non-DEHP metabolites concentrations 
have small estimated effect sizes and the correlations among them are modest, the results across 
models within this group are relatively similar. It may be notable that the largest effect size in this 
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group is for MCPP which, while not significant, comes from a metabolite of a larger molecular 
weight phthalate more similar in structure to DEHP than the other members of this group.  
Since concentrations of the DEHP metabolites, MEHP, MECPP, and MEHHP, are highly 
correlated, the magnitude of their regression coefficients in the single models is similar and is 
notably close to the sum of regression coefficients associated with these three metabolites in the 
Bayesian models. Therefore, when we interpret the regression coefficient in the single models for 
MEHP, MECPP, and MEHHP, we should be cautious that the regression coefficient cannot be 
interpreted as the effect of a single metabolite only. It may represent the overall effect due to a set 
of highly correlated metabolites.  
The concentrations of DEHP metabolites are all highly correlated. Indeed, because 
MEHHP and MEOHP are so highly correlated (r = 0.98), we decided to exclude the latter from our 
regression analyses. Even after this analytic decision, models that include all three of the remaining 
DEHP metabolites exhibit instability, which inflates our problems in parameter estimation in our 
Full OLS model. Since the effects of MEHHP and MEOHP are indistinguishable due to their 
almost perfect correlation, we should be cautious when interpreting the regression coefficient 
associated with MEHHP in a model excluding MEOHP. This coefficient should be interpreted as 
the mean effect on gestational age with a one standard deviation increase in both log-MEHHP and 
log-MEOHP. 
Both Bayesian models stabilize the phthalate parameter estimates by pulling them towards 
the prior mean, but the Bayes-Group model also allows the two other covariates to retain larger 
magnitudes that are more similar to their magnitude in the Full OLS model. This may indicate that 
the more flexible grouped model makes more reasonable assumptions by relaxing the 
exchangeability of the other covariates with the phthalate metabolites. Adding grouping by 
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assigning predictors into classes of similar exposure variables can improve estimation and 
prediction (model fit) where assumptions of exchangeability of all of the predictors may not be 
warranted. Grouping similar classes of variables represents the incorporation of outside 
information. The use of indicators for groups allows sets of parameter estimates to be pulled 
towards separate means, although if additional information were available this could similarly be 
used in this second level of the model. For example, data on the toxicity of individual predictors or 
their constituents which mediate the association between measured predictors and the outcome 
could be used as second level covariates (Witte et al. 1994). 
Previous epidemiologic studies of the phthalates have used two strategies for constructing 
summary variables for the highly correlated predictors in addition to the previously discussed 
single models. The first approach involves the construction of molar sums for high and low 
molecular weight phthalates (summing metabolites > and < 250 Da respectively) (Wolff et al. 
2008). This approach imposes an assumption of molecular equivalence within each class, which is 
a strong assumption in the absence of relevant toxicology data. In addition, the molar sum 
measures can be strongly influenced by the highest concentrations, often MEP and the DEHP 
metabolites for low and high molecular weight phthalates, respectively, which may drown out 
potential true associations with other metabolites. These combination metrics may also be less 
comparable across studies than results from full models, which may measure different sets of 
predictors or where the relative exposure to different contaminants varies substantially such as 
between studies conducted in the US versus in European communities. The second approach to 
combining phthalate metabolites used pretesting for statistical significance of concentrations of 
individual phthalate metabolites (one from each parent compound) and then created a score by 
summing the quartile of concentrations for each of the remaining metabolites of interest (starting 
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from zero for the lowest quartile) (Swan et al. 2005). The selection of variable subsets with 
pretesting (which sets some variables to have β = 0) and the use of combination metrics like the 
low or high molecular weight phthalates or the phthalate quartile score sum can alleviate some of 
the issues of highly correlated predictors. However, these approaches also require strong 
assumptions that may be inappropriate (Greenland 1994), and a loss of information that prevents 
these models from being extended to look at component-specific estimates or interactions.  
 
Challenges in implementing these modeling strategies 
With advances in statistical computing and freely available software such as R and 
WinBUGS, the limitation in fitting more sophisticated models when using biomarker data is 
shifting away from computation and custom programming and relies more on the judgment, 
experience, and technical comfort of the analyst. However, the additional assumptions of the 
Bayesian models require care that model results reflect the data rather than inappropriate prior 
values or model structures. The use of sensitivity analyses that vary prior values can help check the 
appropriateness of models and resulting interpretations. 
We offer the following recommendation for the analysis of biomarker data, when there are 
multiple contaminants or other covariates that are chemically related or have common sources of 
exposure: 
Step 1: Examine the correlation structure among exposures/predictors. Highly correlated 
predictors may require additional modeling strategies.  
Step 2: Fit multiple-variable regression models using Bayesian methods:  
(c) A simple Bayesian model that stabilizes highly correlated predictors by pulling effect 
estimates towards a prior. This is equivalent to ridge regression which is available in 
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many popular statistical packages. It may not be adequate if all effect size estimates for 
predictors are not expected to be similar. 
(d) Bayes model with grouping: by using subject area knowledge, predictors can be 
grouped into subsets that are more reasonably expected to have exchangeable 
parameter estimates. This model can also incorporate additional prior information about 
the effect measures of predictors if it is available. 
 
Conclusions 
Our application is an example of the potential use of Bayesian regression for multiple 
correlated biomarker exposures. Models that include only one of a set of highly correlated 
predictors may be difficult to interpret, and OLS estimation in a full multiple linear model could be 
unstable. We suggest the additional use of simple Bayesian regression strategies to stabilize 
estimates and reduce variance in parameter estimation without relying on strong assumptions or the 
loss of information that can result from using summary measures. Although concentrations of 
several phthalate metabolites are significantly associated with reduced gestational age in single 
models, our data suggests that no single metabolite explains the observed association. Instead, we 
believe that larger (negative) magnitude estimates for MEHP, MEHHP (MEOHP), and MCPP 
indicate that the association with reduced gestational age may be due to exposure to DEHP, DnOP, 
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Assessing potential non-linear associations 
Our previous results modeled concentrations of individual metabolites of DEHP one at a 
time and found both a linear effect and an increase across quartiles that was only statistically 
significant in the fourth quartile (Whyatt et al. 2009). To pursue this further, we plotted 
concentrations of each of the phthalate metabolites one at a time with penalized splines to allow for 
non-linear associations while controlling for premature rupture of membranes and planned 
Cesarean section. Penalized spline regression (Ruppert et al. 2003) results for concentrations of 
single DEHP metabolites and covariates show an association that is inverse and linear, lying 
alongside the line representing the strictly linear model, except for variation at the ends of the 
distribution where there are very few observations reflected in the widening of the 95% credible 
interval. Results for MEHHP, the single metabolite with the largest absolute effect size, are shown 





Figure E1. Penalized spline (with 95% credible interval shaded) shows a decline in 
gestational age with increasing exposure to MEHHP that is consistent with a linear model 
(shown as a dashed line).  




Selection of priors and sensitivity analysis 
The estimated regression coefficients for our set of predictors in a ridge regression model at 
varying levels of shrinkage parameter (λ) are shown in Figure E2. A model fit without shrinkage 
applied on regression coefficients (λ = 0) is equivalent to an ordinary least squares (OLS) linear 
regression model. Although the estimates based on the OLS are asymptotically unbiased, it has the 
widest range for the magnitude of parameter estimates from the phthalates and other covariates. As 
λ increases, the estimates of regression coefficients are penalized to shrink toward zero, and 
estimated prediction error is reduced to a point, measured here by a local minimum for the 
generalized cross-validation statistic. Notably, as the shrinkage increases the highly correlated 
predictors MECPP and MEHHP are pulled towards zero more rapidly than the uncorrelated other 
covariates. As λ increases further, the magnitudes of coefficient estimates continue to reduce, but 
the estimated prediction error increases as well. An excess of shrinkage will pull parameter 
estimates too far towards zero with infinite shrinkage equivalent to an intercept-only model which 
will have poorer model fit than a more judicious use of predictor variables. Because the 
generalized cross-validation (GCV) statistic is easily computed, it was selected as a metric to select 
the amount of shrinkage that corresponded to the optimal bias-variance tradeoff by minimizing the 
generalized cross-validation based prediction error. 
Because the amount of shrinkage in the Bayesian models we used is a function of both the 
data and the priors, it is important to conduct sensitivity analyses to understand the role of prior 
distribution parameters in these results. Our selection of prior variance values from our own dataset 
corresponds to the previously described “semi-Bayes” strategy (Greenland 1994). 
Several previously published studies that advocated using Bayesian models for multiple 
exposure models were based on applications with multiplicative models for dichotomous outcomes 
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such as cancer, infant mortality, and retinal degeneration (De Roos et al. 2001; De Roos et al. 
2003; Greenland 1994; MacLehose et al. 2007; Momoli et al. 2010; Witte et al. 1994). The authors 
of these papers advocate selection of a prior variance based on a reasonable multiplicative range 
for parameter estimates (e.g. a belief that 95% of estimates will be within 16-fold of each other). 
Unfortunately, this appealing and understandable interpretation isn’t applicable to the additive 
model used with our continuous outcome of gestational age in weeks. The optimization of the 
generalized cross-validation statistic offers an alternative approach for selecting a prior variance 





Figure E2. Lines in the top panel show parameter estimates and the bottom panel shows the 
generalized cross-validation statistic (GCV) with different amounts of shrinkage, λ, from 
ridge regression.  
Line labels show that MECPP and MEHHP, the two highly correlated DEHP metabolites with the 
most widely spread estimates at λ = 0 are pulled towards 0 more rapidly with increasing λ  than 
other variables, particularly planned Cesarean section. The vertical dotted line corresponds to the 
level of λ which minimizes the GCV. 
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R Code to fit these simple Bayesian models 
The following annotated code runs two simple Bayesian multivariable regression models 
for a continuous outcome that has been centered; (1) a simple model we call “Bayes-Ridge” with 
priors centered on zero and a fixed error term and (2) “Bayes-Group”, a model with a more flexible 
error structure and prespecified grouping of similar predictors. This code was tested on a Windows 
7 system using both R version 2.12.2 (R Development Core Team 2011), run as administrator with 
packages “arm” (Gelman et al. 2011), “MASS” (Venables and Ripley 2002), and their 
dependencies including “R2WinBUGS” (Sturtz et al. 2005) installed, as well as WinBUGS 1.4.3 
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R code for WinBUGS models 
################################################### 
# R code for WinBUGS models 
# with correlated predictors and a continuous outcome 
 
# February 2011  




# This file fits two simple bayesian models as described in comments below 
 
# We assume the user starts with a data frame in the  
# local environment named 'dataframe' and has installed WinBUGS 
# available at www.mrc-bsu.cam.ac.uk/bugs/ 
 
# we assume that the centered outcome is the first column 
# and that all remaining columns are standardized predictors 
# note that the code as written does not accommodate extraneous variables 
# and it restricts to complete data 
 
# For the Bayes model which assumes grouping of covariates, 
# the model expects the columns to be sorted so that the covariates in 
# groups are together. In the following code, we assume 3 groups  
# with 5, 3, and 2 covariates respectively. 
 
## load libraries 
library(arm) #also loads R2WinBUGS 
library(MASS)#contains lm.ridge function 
 
## local functions 
#  
# ridge.search.gcv 
# Description - function to explore local values around crude best GCV 
# Arguments: 
# ridgecall- a symbolic description of the formula to be fitted,  
#            the linear predictor. see ?formula. 
# data     - specify the dataset, which is of class data.frame 
# lambda   - vector of initial shrinkage parameter values over which to  
#            search. Best initial value is the one which minimizes GCV  
#            (generalized cross validation). Must be non-negative. 
# lambdasearch - distance +/- from best initial lambda to explore,  
#            over steps of 0.1. default is 10. 
# verbose  - option to print intermediate results:  best initial lambda,  
#            best lambda on local search, and regression coefficients  
#            from ridge model; default is FALSE. 
# Results: 
# returns the optimal estimated shrinkage parameter lambda based on GCV. 
 
ridge.search.gcv <- function( 
ridgecall, data, lambda, lambdasearch = 10, verbose = F){ 
 lambda.gcv <- lm.ridge(ridgecall, data = data, lambda = lambda) 
 best.lambda1 <- which.min(lambda.gcv$GCV) 
 if(verbose){ 





 # create a series of lambda values nearby (non-negative) 
 local.lambda <- round(lambda.gcv$lambda[best.lambda1], 0.1) 
 local.lambda <- seq(max(0, local.lambda - lambdasearch), 
  local.lambda + lambdasearch, 0.1) 
 lambda.refit <- lm.ridge(ridgecall, data = data, lambda = local.lambda) 
 
 # warn if lowest GCV is at the boundary of tested lambdas 
 if(which.min(lambda.refit$GCV) %in% c(1, length(local.lambda))){ 
  warning("lowest GCV at boundary,\n try larger lambdasearch") 
 } 
 best.lambda2 <- which.min(lambda.refit$GCV) 
 if(verbose){ 
print(paste("best lambda on local search is", names(best.lambda2))) 
  print(coef(lambda.refit)[best.lambda2, ]) 
 } 
 invisible(as.numeric(names(best.lambda2)))  
 # returns the optimal lambda without printing 
}  
 
# rsd: Extracts the residual standard deviation (from a linear model object) 
# Arguments:  x which is an object of class "lm" 
rsd <- function(x) summary(x)$sigma 
 
###################################### 
## defining the model formula 
# (column 1 ~ remaining columns) 
formula.bugs <- formula(dataframe) 
# remove the intercept term 
formula.bugs <- update(formula.bugs, ~ -1 + .) 
# IMPORTANT: this is the formula that will be fit for the Bayes models 
print(formula.bugs) 
 
# check that there is a data.frame named “dataframe” 
if(!exists("dataframe")) warning("need an object named 'dataframe'") 
if(!is.data.frame(dataframe)) warning("'dataframe' must be a data.frame") 
# restrict the dataset to complete cases 
dataframe <- dataframe[complete.cases(dataframe), ] 
 
################################################### 
# linear regression; no intercept model formula 
BR <- lm(formula.bugs, data = dataframe) 
display(BR) 
 
# prespecified model errors (sigma.y.fixed) 
# and model prior variance (tau.fixed) 
sigma.y.fixed <- round(1/(rsd(BR)^2) , 2) 
sigma.y.fixed # model error from linear model 
lambda.gcv <- ridge.search.gcv(formula.bugs, dataframe,  
 lambda = c(0, exp(1:10)), lambdasearch = 100, verbose = T) 
tau.fixed <- round(1 / (rsd(BR)^2/lambda.gcv), 2) 
tau.fixed # inverse of ratio of rsd^2 and lambda.gcv 
 
# program a bugs file “BR.bug”, saved to working directory 
# uses the gcv from ridge regression to select the amount of shrinkage 





 for (i in 1:n){ 
  y[i] ~ dnorm(mu[i], ", sigma.y.fixed, ") 
  mu[i] <- inprod(x[i, ], beta[]) 
 } 
 ### Priors 
 for (p in 1:10)(beta[p] ~ dnorm(0, ", tau.fixed, ")) 
 }", 
 sep = "", file = "BR.bug") 
file.show("BR.bug") 
 
y <- dataframe[, 1] # outcome 
n <- length(y)  # number of observations 
x <- as.matrix(dataframe[, -1]) # design matrix 
j <- dim(x)[2] # number of parameters in model matrix 
BR.data <- list ("n", "y", "x") 
# starting values for parameters; set to 0 
BR.inits <- function()list(beta=rep(0, j))  
BR.parameters <- c("beta") 
 
# run in winbugs1.4 – this can take a few seconds 
BR.out <- bugs(BR.data, BR.inits, BR.parameters, 
 "BR.bug", n.chains=3, n.iter=500, debug = FALSE) 
 
# display the results on console using variable names from dataframe 
dimnames(BR.out$summary)[[1]][1:j] <- dimnames(x)[[2]] 




# model BG (Bayes-Group)  
# like model P2 in MacLehose et al. 2007, it places a distribution on both 
# the model error (sigma.y with a minimally informative prior) 
# and the variance of the prior on parameters (tau). 
# it also separates covariates into 3 groups (similar to Momoli et al. 2010). 
# these are mutually exclusive groups of our 1:p predictors 
# here we use 1:5, 6:8, and 9:10 
# otherwise the structure of the R and bugs code is  
# similar to Bayes-Ridge above 
 
# revisiting the form of the linear predictor 
formula.bugs 
# linear regression of our no-intercept model formula 
BG <- lm(formula.bugs, data = dataframe) 
display(BG) 
 
# prespecified model errors (sigma.y.fixed) 
# and model prior variance (tau.fixed) 
sigma.y <- round(1/(rsd(BG)^2) , 2) 
sigma.y # model error if you were using ridge 
lambda.gcv <- ridge.search.gcv(formula.bugs,  
 dataframe, lambda = c(0, exp(1:10)), lambdasearch = 100, verbose = T) 
tau.fixed <- round(1 / (rsd(BG)^2/lambda.gcv), 2) 
tau.fixed # inverse of ratio of rsd^2 and lambda.gcv 
 
# program a bugs file “BG.bug”, saved to working directory 
#102 
 
# uses the gcv from ridge regression to select the amount of shrinkage 
cat("#  
 # Model BG.bug 
 # like model P2 in MacLehose, it has a prior on both  
 # model error, tau.y, 
 # and on the prior variance for betas, tau 
 # it also has three separate group means for regression parameters; 
 model 
 { 
 for (i in 1:n){ 
  y[i] ~ dnorm(mu[i], sigma.y) 
  mu[i] <- inprod(x[i, ], beta[])} 
 ### Priors by group 
 for (p in 1:5)(beta[p] ~ dnorm(theta0, tau))  
 for (p in 6:8)(beta[p] ~ dnorm(theta1, tau))  
 for (p in 9:10)(beta[p] ~ dnorm(theta2, tau))  
  
theta0 ~ dnorm(0, 1) 
 theta1 ~ dnorm(0, 1) 
 theta2 ~ dnorm(0, 1) 
 tau ~ dgamma (", tau.fixed, ", 1) 
 sigma.y <- pow(inv.sigma.y, -2)  # inv.sigma.y = 1/sigma^2 
 inv.sigma.y ~ dunif(0, 1000)  # noninformative prior 
 }", 
 sep = "", file = "BG.bug") 
file.show("BG.bug") 
 
## the entire code, as written, fits 2 Bayesian models 
## if not run earlier, run the following 4 commented lines 
# y <- dataframe[, 1] 
# n <- length(y) 
# x <- as.matrix(dataframe[, -1]) 
# j <- dim(x)[2] #  number of parameters in model matrix 
 
BG.data <- list ("n", "y", "x") 
BG.inits <- function() list(beta=rep(0, j), sigma.y = 1,  
tau = tau.fixed, theta0 = 1, theta1 = 1, theta2 = 1) 
BG.parameters <- c("beta", "sigma.y", "tau", "theta0", "theta1", "theta2") 
 
# run in winbugs1.4  
# this can take a few moments while the model updates 
BG.out <- bugs(BG.data, BG.inits, BG.parameters, 
 "BG.bug", n.chains=3, n.iter=750, debug = F) 
 
# display the results on console using variable names from dataframe 
dimnames(BG.out$summary)[[1]][1:j] <- dimnames(x)[[2]] 
print (BG.out, digits = 2) 
#plot (BG.out) 
# End of Code ################################ 
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Background: Recent cross-sectional studies suggest a link between butylbenzyl phthalate 
(BBzP) in house dust and childhood eczema. 
Objectives: To evaluate whether monobenzyl phthalate (MBzP), the main BBzP 
metabolite in maternal urine, during pregnancy is associated prospectively with eczema in young 
children, and whether this association varies by the development of seroatopy in the child. 
Methods: MBzP was measured in spot urine samples collected during the 3rd trimester of 
pregnancy from n=407 African American and Dominican women residing in New York City in 
1999-2006. Repeated questionnaires asked mothers whether their doctor ever said their child had 
eczema. Child blood samples at ages 24, 36, and 60 months were analyzed for total, anti-
cockroach, dust mite, and mouse IgE. Analyses included a multinomial logistic regression model 
for early and late onset eczema versus no eczema through age 60 months. Relative risks were 
estimated with multivariable modified Poisson regression. 
Results
Conclusions: Prenatal exposure to BBzP may influence the risk of developing eczema in early 
childhood. 
: MBzP was detected in >99% of samples (geometric mean 18.9, interquartile 
range 8.0, 43.2 ng/ml). By 24 months, 30% of children had developed eczema, with the 
proportion higher among African Americans (48%) than Dominicans (21%) (p<0.001). MBzP 
concentrations were associated positively with early onset eczema (relative risk 1.52 for eczema 
by 24 months, 95%CI [1.21, 1.91], p<0.001, n=376) for an interquartile range increase in log 
MBzP concentration, adjusting for specific gravity, sex, and ethnicity. MBzP was not associated 





Eczema, a type of persistent itchy skin rash, in children is considered an early manifestation 
of allergic disease, and can mark the beginning of the “atopic march” (Leung et al. 2004). 
Although exposure to allergens may be important in the development of eczema, exposure to other 
environmental agents has been implicated as well. For example, in cross-sectional studies, 
environmental tobacco smoke, semi-volatile contaminants of indoor air such as propylene glycol, 
glycol ether and butylbenzyl phthalate (BBzP), and residential renovation around the time of birth 
have been associated with eczema in young children (Bornehag et al. 2004; Choi et al. 2010; 
Herbarth et al. 2006; Kramer et al. 2004). Results from a 2003 U.S. national survey suggest that 
living in urban areas, African American race, higher parental education, and child-care attendance 
are associated with an increased prevalence of childhood eczema (Shaw et al. 2011). Further, either 
atopic or nonatopic eczema (also referred to as intrinsic or nonallergic eczema) may develop in 
childhood. The two phenotypes differ in their risk factors and in their immunopathogenesis (Kusel 
et al. 2005). 
Some phthalates are added to plastics to increase flexibility and are common components 
of consumer products including flooring materials and certain plastic household products. BBzP is 
a common component of vinyl flooring and is found frequently in house dust and indoor air (Adibi 
et al. 2008; Kolarik et al. 2008a). Monobenzyl phthalate (MBzP), the main BBzP metabolite, was 
detected in greater than 97% of urine samples in the U.S. representative 1999-2000 National 
Health and Nutrition Examination Survey (NHANES) (Silva et al. 2004), and detection in amniotic 
fluid indicates transplacental exposure during pregnancy (Wittassek et al. 2009). Although diet is 
believed generally to be the largest contributor to BBzP exposure in adults (Wormuth et al. 2006), 
in the Columbia Center for Children’s Environmental Health (CCCEH) study we reported that 
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concentrations of BBzP collected in 48-hour personal air samples during pregnancy correlated with 
concentrations of MBzP in paired maternal spot urine samples (Spearman’s Rho: 0.48, p<0.05, 
n=62) (Adibi et al. 2008). Hence, non-dietary routes, including inhalation, also may be important. 
House dust concentrations of several phthalates were measured in a Swedish case-control 
study comparing case children with physician-confirmed persistent eczema, rhinitis, or wheezing 
without a cold, with asymptomatic controls. Median concentrations of BBzP in bedroom dust were 
significantly higher among children with physician diagnosed eczema and rhinitis versus healthy 
children with a positive dose-response trend in the odds ratio across quartiles of exposure 
(Bornehag et al. 2004). Polyvinyl chloride (PVC) flooring, considered an important source of 
phthalate plasticizers in the home, also was associated significantly with eczema and rhinitis. 
Additionally, higher concentrations of di(2-ethylhexyl) phthalate (DEHP), a common PVC 
plasticizer, were found in bedroom dust of cases with asthma compared with controls. The 
Swedish study design was replicated in Bulgaria where BBzP concentrations were higher in the 
house dust of children reporting wheeze or eczema, but the difference was not statistically 
significant (Kolarik et al. 2008b). While these findings are suggestive of a role of BBzP in the 
development of eczema, the use of urinary biomarkers offers a more direct measure of individual 
exposure than house dust by integrating ingestion, inhalation, and dermal absorption. In addition, 
longitudinal studies may offer further insight into the timing of exposure relative to disease onset.  
 The purpose of our study was to investigate whether prenatal measures of BBzP are associated 
with eczema and sensitization to common indoor aeroallergens in early childhood in an urban birth 
cohort. We hypothesized that prenatal BBzP would be associated with increased risk of eczema 




As part of the CCCEH birth cohort, non-smoking pregnant Dominican and African 
American women were recruited during the third trimester and n=727 fully enrolled mother-child 
pairs were followed prospectively as previously described (Perera et al. 2003). Participants for the 
current analysis (n=407) had prenatal urinary phthalate metabolites measured (n=426/727) and 
responded to at least one questionnaire on eczema between child age 3 and 60 months. Study 
procedures, including questionnaires and collection of biologic samples, were explained to 
participants at enrollment and a signed consent, approved by the institutional review boards of 
Columbia University and the Centers for Disease Control and Prevention (CDC), was obtained. 
Spot urine samples were collected during the third trimester (mean gestational age 34 
weeks, interquartile range (IQR) 32 to 36 weeks) from 1999-2006 and analyzed for metabolites of 
BBzP and several other phthalates at the National Center for Environmental Health of the CDC as 
described (Adibi et al. 2008; Kato et al. 2005). The specific gravity of the urine was measured 
using a handheld refractometer (Atago PAL 10-S, Bellevue, WA). 
 Eczema was assessed by questionnaires administered to the mother by telephone and in-
person at repeated visits by asking: “Has your doctor ever said that your child has eczema?” Four 
questionnaires were administered in each of the first two postnatal years and another four 
questionnaires between ages 24 and 60 months (for a maximum of 12 questionnaires). Two-thirds 
of participants answered at least 9 questionnaires over the 12 possible time-points. At age 60 
months the International Study of Asthma and Allergies in Childhood (ISAAC) core eczema 
module (Asher et al. 1995) also asked “Has your child ever had an itchy rash which was coming 
and going for at least 6 months?”, and among those who responded positively “Has your child had 
this itchy rash at any time in the last 12 months?” 
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 Sera were collected from the children during visits at ages 24, 36, and 60 months. 
Seroatopy was defined as a positive ( ≥0.35 IU/ml) specific IgE to cockroach, dust mite, or mouse 
in any available sample by ImmunoCap (Phadia, Uppsala, Sweden) (Chang et al. 2010; Donohue 
et al. 2008).  
 
Statistical analysis 
 Descriptive statistics were compared among data subsets with t-tests and chi-square tests for 
continuous and categorical variables respectively. Urinary concentrations of MBzP were log 
transformed prior to analysis. Specific gravity was retained as a covariate in all models to account 
for variation in urinary dilution (Barr et al. 2005). One participant with a concentration of MBzP 
below the limit of detection (0.3 ng/ml; specific gravity 1.005) was excluded from further analysis 
because imputing a concentration of half the limit of detection and subsequent log transformation 
of the predictor created an influential point in the regression. Sensitivity analysis showed that 
parameter estimates excluding this sample did not differ from those in which 1 ng/ml was added to 
all concentrations prior to log transformation.  
Eczema was reclassified as early onset eczema if it was reported on any questionnaire 
through 24 months of age. This combined variable for early onset eczema was restricted to 
children with at least one of four completed questionnaires in the first year, and one of four in the 
second year (n=376). Data on seroatopy using specific IgE were available for 94% of these 
children (n=355). Eczema was reclassified as late onset eczema if the first report of ever eczema 
was reported between age 24 months and 60 months among participants who completed at least 
one of four questionnaires in the first year, one of four in the second year, and one of four in the 
third through fifth year. A multinomial logistic regression model for early and late onset eczema 
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versus no eczema through age 60 months as the referent group was performed, restricted to 
participants who remained enrolled through 60 months (n=339). 
 A modified Poisson regression was used to generate relative risk (RR) regression parameters and 
variance estimates (Zou 2004). Although this is a multiplicative model, potential interactions 
between risk factors were tested as a departure from additivity using the relative excess risk due to 
interaction (RERI) (Rothman et al. 2008), with 95% confidence intervals from percentiles of 10000 
bootstrap samples (Knol et al. 2007). Statistical analyses were conducted in R version 2.13.0 (R 
Development Core Team 2011) with the “effects” package for the confidence interval on a 
multinomial model and “ggplot2” package for graphics (Fox and Hong 2009; Wickham 2009). 
 
Results  
Cohort characteristics  
Demographic characteristics of the n=407 mother-child pairs included in analyses and the 
remainder of the CCCEH cohort are described in Table 1. Participants included in analyses did not 
differ in major demographic characteristics from the remainder of the CCCEH cohort, except that 
they were less likely to have prenatal exposure to environmental tobacco smoke (31% versus 39%) 
and had less seroatopy at 24 months (8% versus 17%) in available samples; although, seroatopy 
did not differ at 36 or 60 months or when combined as described in methods. MBzP was detected 
in all except one urine sample and concentrations ranged widely (geometric mean (GM) of 18.9, 
IQR [8.0, 43.2] ng/ml). MBzP concentrations were higher among African American (GM 25.5, 
IQR [12.1, 49.2] ng/ml) than Dominican women (GM 16.2, IQR [6.8, 36.6] ng/ml) (p<0.001). 
There was no association between prenatal MBzP urinary concentrations and self report of 




Eczema characteristics  
By child age 24 months, 30% of mothers had reported at least once that their doctor had 
ever said that their child had eczema, with a higher proportion among African American (48%, 
n=62/129) than Dominican (21%, n=51/247) children. Among Dominicans, the proportion of 
mothers reporting eczema in their children by language of questionnaire administration (English 
versus Spanish) was the same. There was no difference in the proportion of children with ever-
eczema by child sex overall (32% female, 28% male, p=0.37) or after stratifying by race/ethnicity 
(not shown). The proportion of children with ever eczema generally increased with the child’s age, 
from 10% at age 3 months to 28% at age 60 months. However, women were sometimes 
inconsistent in their report of their child’s eczema. Among those who had a positive report of ever-
eczema (at any of the 12 questionnaire time-points), 59% of subsequent questionnaires were also 
positive. 
 
MBzP and eczema 
Adjusted RR estimates of child ever-eczema for an IQR increase in prenatal MBzP urinary 
concentrations at each of 12 questionnaire time-points are shown in Figure 1. Relative risks appear 
to be consistently positive with larger magnitudes, suggesting a stronger association, at the earlier 
ages. Prenatal MBzP urinary concentration was associated positively with any report of eczema by 
24 months (RR 1.52, 95%CI [1.21, 1.91], p<0.001, n=376) for an IQR increase in log MBzP 
concentration after adjusting for specific gravity of the urine, sex, and ethnicity. The parameter 
estimate for child’s sex was not significant in the multivariable model with a RR for males versus 
females (reference) of 0.82 (95%CI [0.60, 1.10], p=0.18). The prenatal MBzP estimate for any 
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report of eczema by 24 months had a similar magnitude in a logistic regression model (OR 1.99, 
95%CI [1.34, 2.97], n=376) as in a multinomial analysis separately fitting ORs for inconsistent 
reporters who said no ever-eczema after having said yes ever-ezcema (OR 1.98, 95%CI [1.23, 
3.17], n=63) and for consistent reporters (OR 2.02, 95%CI [1.19, 3.43], n=50) versus none 
(n=263). To determine whether the association between prenatal MBzP concentrations and eczema 
was greater among children with early onset (by 24 months) versus late onset eczema, multinomial 
analyses were performed (n=339) after reclassifying eczema as early (29%, n=100), late (13%, 
n=43), or none (58%, n=196). MBzP concentration was associated positively with early onset 
eczema (adjusted OR 1.91, 95%CI [1.23, 2.97] for an IQR change; Figure 2). There was no 
association between MBzP and late onset eczema, with an adjusted OR of 0.90 (95%CI [0.51, 
1.58]) for an IQR change in log MBzP from the multinomial analysis. Moreover, there was no 
association between MBzP concentration and the recent symptom report at 60 months of “itchy 
rash at any time in the past 12 months that was coming and going for at least 6 months” (RR 1.23, 




Figure 1. Relative risk estimates of child ever-eczema for an interquartile range (IQR) 
increase in prenatal log MBzP urinary concentration adjusting for specific gravity, ethnicity, 
and sex from separate regression models using questionnaire data collected at 12 different 




Figure 2. Probability of no eczema, early onset eczema (by 24 months), and late onset eczema 
(30 to 60 months).  
Each line is the modeled probability of belonging to a group for a given log concentration of MBzP 
and the mean specific gravity, sex, and maternal ethnicity. A 95%CI is shown for the early onset 




MBzP and eczema by ethnicity 
Because previously we reported that eczema may vary by race/ethnicity (Donohue et al. 
2008), we sought to understand better whether the association between phthalates and eczema was 
modified by ethnicity. Maternal African American versus Dominican ethnicity was a significant 
predictor of report of eczema by 24 months (RR 2.09, 95%CI [1.53, 2.86], p<0.001) after adjusting 
for MBzP concentration, specific gravity, and sex. There was a consistently higher probability of 
eczema for African Americans across the range of urinary concentrations of MBzP. Both ethnic 
groups had similar slopes for the exposure-response curve in stratified analysis, indicating a lack of 
multiplicative interaction (Figure 3). However, there was a nonsignificant greater than additive 
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interaction between African American ethnicity and each IQR increase in MBzP urinary 
concentration (RERI 0.54, Bootstrap 95%CI [-0.07, 1.39]). 
 
 
Figure 3. Association between prenatal urinary concentration of MBzP and report of eczema 
by 24 months plotted as probability from a multivariable logistic regression adjusted with 
mean specific gravity and sex.  
The y-axis is shown on the logit scale. The overall cohort model is shown in black with 95%CI in 
grey. The ethnic subsets are shown in dashed and dotted lines for African Americans and 
Dominicans. Although the baseline probabilities differ in the two subsets, the overall association 
remains positive with increasing urinary concentrations of MBzP. 
 
MBzP, eczema, and seroatopy 
A total of 26% (n=91/355) of children were classified as seroatopic to indoor aeroallergens 
at age 24, 36, or 60 months. Among children with eczema by 24 months, 29% (n=31/106) were 
seroatopic and 71% (n=75/106) were non-seroatopic. This proportion of seroatopics was similar 
among children without eczema (24%, n=60/249) (p=0.31). Children with eczema by 24 months 
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on average developed higher total IgE levels at age 60 months compared to children without 
eczema, regardless of whether they were defined as non-atopic (GM: 39 IU/ml, n=67 versus 24 
IU/ml, n=152; p=0.016) or seroatopic to indoor aeroallergens based on their age 60 month specific 
IgE values (GM: 207 IU/ml, n=22 versus 107 IU/ml, n=50; p=0.056). 
There was no observed association between prenatal MBzP urinary concentration and 
seroatopy to indoor aeroallergens (RR 0.89, 95%CI [0.68, 1.16], p=0.81, n=355). Similarly, there 
was no observed association between MBzP concentration and log total IgE at 60 months (?̂? -0.14, 
95%CI [-0.41, 0.13], p=0.29, n=306) for an IQR change in MBzP concentration controlling for 
specific gravity, ethnicity, and sex. We also examined whether the association between prenatal 
MBzP urinary concentration and eczema differed by seroatopy to any one of three indoor 
aeroallergens. There was no significant interaction between seroatopy and higher MBzP 
concentration (continuous term) in predicting eczema using the RERI to test for departures from 
additivity, indicating that the MBzP urinary concentration and eczema association did not 
significantly vary by seroatopy (RERI 0.13, Bootstrap 95%CI [-0.29, 0.41]).  
 
Other phthalates and eczema 
Although urinary concentration of the metabolites of several other phthalates are correlated 
moderately with MBzP, in models with both prenatal MBzP and mono-n-butyl phthalate (a major 
metabolite of di-n-butyl phthalate and a minor metabolite of BBzP) or mono(2-ethyl-5-
hydroxyhexyl) phthalate (metabolite of DEHP) urinary concentrations, only MBzP was a 





We report here a novel association between prenatal urinary concentrations of MBzP, the 
main metabolite of BBzP, and the subsequent report of childhood eczema among African 
American and Dominican children in New York City. The association appears to be primarily 
among those with early onset eczema, reported by 24 months of age. Although the proportion of 
children with eczema is higher in African Americans than Dominicans, in both groups there is a 
similar positive association between prenatal urinary concentrations of MBzP and early onset 
eczema. No association was observed between prenatal urinary concentration of MBzP and 
seroatopy, as measured by specific IgE against three indoor allergens. These prospective results 
extend previous cross-sectional results nested in a Swedish cohort linking house dust 
concentrations of BBzP and eczema in a dose-response manner (Bornehag et al. 2004). While 
Swedish case children with physician-diagnosed eczema or rhinitis had statistically significantly 
higher BBzP concentration in their bedroom dust than controls, consistent with the findings here, 
there was no difference in BBzP concentration between atopic and non-atopic cases as classified 
by specific IgE (Bornehag et al. 2004). 
One particular strength of the current study is the use of a urinary biomarker of phthalate 
exposure that has been shown previously in this population to have a good reproducibility over late 
pregnancy (ICC=0.66 for MBzP sampled 2-4 times over 6 weeks) (Adibi et al. 2008). In addition, 
the prospective birth cohort design allows a clear temporal order in which the measure of prenatal 
exposure precedes the development and subsequent report of children’s health outcomes. It also 
has enabled us to evaluate the association between prenatal exposure to BBzP and early versus late 
onset eczema based on the age at first report. We observed that associations between prenatal 
urinary concentrations of MBzP and eczema had larger effect size estimates on questionnaires 
#117 
 
collected at earlier ages than those after 24 months. In our multinomial analysis, MBzP urinary 
concentration was associated with early but not late onset eczema (first report after 24 months) 
relative to those in the no eczema group. Neither of the two major risk factors for early onset 
eczema, MBzP concentration and African American race/ethnicity, were associated with late onset 
eczema. Furthermore, fitted values from the full multinomial model did not predict any members 
of the late eczema group. Because late eczema was less common (13%, n=43/339), this finding 
may have been due partially to the instability of estimating associations for this small group and 
may not indicate that late onset eczema is a different clinical phenotype in this cohort.  
Given the known association between eczema and atopy, we also hypothesized that 
exposure to BBzP would be associated with seroatopy to three indoor aeroallergens. This 
hypothesis was based on experimental evidence with other phthalates that may have relevance to 
BBzP. These include ex vivo experiments on human peripheral blood mononuclear cells incubated 
with DEHP, or its hydrolytic metabolite mono(2-ethylhexyl) phthalate (MEHP), that produced 
greater proallergic cytokine levels and histamine release (Glue et al. 2002; Glue et al. 2005; 
reviewed in Kwak et al. 2009). In addition, prenatal and neonatal exposure of mice to DEHP 
induced an atopic dermatitis-like phenotype in dust mite sensitized offspring that was characterized 
by greater local expression of the proallergic chemokine eotaxin (Yanagisawa et al. 2008). 
Interestingly, another phthalate, di-n-butyl phthalate, has been shown to upregulate proallergic skin 
hypersensitivity reactions via thymic stromal lymphopoietin (TSLP), a cytokine known to activate 
the maturation of dendritic cells and recently associated with eczema, in mice (Larson et al. 2010; 
Shigeno et al. 2009). 
However, we observed that in this cohort MBzP urinary concentration was not associated 
with seroatopy, despite its association with eczema, suggesting that exposure to BBzP may 
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increase the risk of eczema through a non-allergic mechanism. This finding may be consistent with 
two studies in which BBzP failed to act as an adjuvant in mouse models of allergic sensitization 
(Dearman et al. 2009; Larsen et al. 2003). While eczema is considered frequently an early indicator 
of IgE-mediated allergic diseases (Leung et al. 2004), it should be noted that eczema among non-
atopic children also is quite prevalent. As high as two-thirds of children with eczema are nonatopic 
in population-based studies (Flohr et al. 2004); in this cohort, 71% of those with reported eczema 
did not have seroatopy. Further, evidence suggests that immunopathogenesis of eczema can be 
triggered by mechanisms unrelated to allergic sensitization. For example, interleukin 31 has been 
implicated specifically in nonatopic eczema, and can induce the expression of several chemokines, 
including TARC/CCL17 (thymus- and activation-regulated chemokine) and MDC (macrophage-
derived chemokine)/CCL22, important to the recruitment of inflammatory cells to the skin (Dillon 
et al. 2004; Schulz et al. 2007). Exposure to diisononyl phthalate, while not evaluated in this study, 
was shown likewise to induce the production of TARC/CCL17 and MDC/CCL22 in mice (Koike 
et al. 2010), although mediation via interleukin 31 has not yet been reported. Several phthalate 
metabolites, including MEHP and mono-n-octyl phthalate, but not MBzP, also have been shown to 
stimulate interleukin 8 in cell systems that could trigger a cascade of nonallergic proinflammatory 
events relevant to eczema (Jepsen et al. 2004). Finally, BBzP acts as an agonist of the peroxisome 
proliferator-activated receptors (PPARα and PPARγ) (Hurst and Waxman 2003). While the few 
studies that have examined immunologic responses to other PPAR agonists suggest that they 
suppress rather than induce skin inflammation (Jung et al. 2011; Staumont-Salle et al. 2008), it 
remains an open question whether interference with the PPARs could be one potential mechanism 
through which BBzP might affect the development of eczema.   
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The development of eczema related to phthalate exposure may vary by race/ethnicity in this 
cohort. The joint effect of an IQR increase in MBzP urinary concentration and African American 
race/ethnicity resulted in a relative risk estimate that was 0.54 higher (Bootstrap 95%CI on RERI [-
0.07, 1.39]) than the expected sum of the main effects estimated in the absence of interaction, 
although this additive interaction did not reach statistical significance. We speculate that 
differences in dietary patterns as well as differences in the prevalence of indoor materials such as 
vinyl flooring made with BBzP, may contribute to the observed higher urinary concentrations of 
MBzP among African Americans. Differences in eczema prevalence by race have been reported 
previously. For example, in the 2003 National Survey of Children's Health, 9.7% of White-only 
and 15.9% of Black-only households reported eczema in the previous year. Race remained a 
significant predictor after controlling for a number of potential confounders also associated with 
higher eczema such as young child age, higher level of education, higher family income, and 
residence in a metropolitan area (Shaw et al. 2011).  
We acknowledge several limitations. There was no assessment of early postnatal exposure 
to phthalates. Child eczema was assessed via questionnaire and therefore subject to a lack of 
standardization, misclassification or recall bias. The lack of full consistency in subsequent 
questionnaires after first report of ever-eczema may be an indication of this potential 
misclassification. However, our query: “Has your doctor ever said that your child has eczema?” 
has been validated by physician diagnosis in a study of Oregon school children (Laughter et al. 
2000). We also have no reason to believe that any misclassification would be differential by 
phthalate exposure and thus should only bias the effect estimates towards the null. Although one 
could categorize participants by the first time when they reported ever-eczema, the exact age of 
onset only can be inferred indirectly from the questionnaire. Additionally, some of the differences 
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in the report of eczema by ethnicity may partially reflect differences in the understanding of what 
constitutes “eczema”, although there were no differences in report between English and Spanish 
speaking Dominican participants. In addition, the contribution of food allergy to MBzP-associated 
early eczema was not assessed and the higher total IgE among those with eczema than those 
without eczema suggests that sensitization to unmeasured allergens might be associated with 
eczema here. We also cannot rule out that children classified as non-atopic may later develop 
seroatopy.  
The exposure monitoring found wide variation in prenatal exposure to BBzP in this urban 
population. Although dietary contamination as well as vinyl flooring are thought to be important 
sources for BBzP exposure, a dietary intervention failed to reduce exposure to BBzP (Rudel et al. 
2011), and we are aware of no prior studies evaluating household interventions on phthalate 
containing products and materials. However, experience with other phthalates demonstrates that 
regulatory policies and market pressures can modify population-level exposures. For example, 
German industrial production of DEHP and exposure among students ages 20-29 were highly 
correlated (Helm 2007), and research suggests that a changing exposure profile for BBzP and other 




Using a longitudinal urban US birth cohort, we found novel results that suggest that MBzP 
urinary concentrations measured prenatally are associated with early onset eczema. This finding 
was unrelated to seroatopy. Future studies may extend our findings using intervention designs to 
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test whether early-life exposure to BBzP can be reduced and whether this leads to a reduction in 
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Rationale: Phthalates are widely used in consumer products, and exposure to several have been 
associated with respiratory symptoms and decreased lung function. Associations between 
children’s phthalate exposures and fractional exhaled nitric oxide (FeNO), a biomarker of airway 
inflammation, have not been examined.  
Objectives: We hypothesized that urinary concentrations of four phthalate metabolites would be 
associated with higher FeNO, and these associations would be stronger among children with 
seroatopy or wheeze. 
Methods: In an ongoing birth cohort in New York City, 280 children without a cold had phthalate 
metabolites analyzed in spot urine samples collected within one week of an FeNO measure. 
Repeated sampling gathered a total of n=373 observations between ages 4.9-9.5 years and 
regression models used generalized estimating equations. Seroatopy was assessed by specific IgE 
to cockroach, dust mite, or mouse allergens. Wheeze in the past 12 months was assessed with a 
validated questionnaire.  
Measurements and Main Results: Log-unit increases in urinary metabolites of diethyl phthalate 
(DEP) and butylbenzyl phthalate (BBzP) were associated with a 6.1% (95% confidence interval 
[CI] 0.2%, 12.4%) and 8.2% (95% CI 1.7%, 15.1%) increase in FeNO, respectively, adjusting for 
the other phthalate metabolites, specific gravity, seroatopy, sex, age, race/ethnicity, and ambient 
nitric oxide. There was no association between urinary metabolites of di(2-ethylhexyl) phthalate 
(DEHP) or di n-butyl phthalate (DnBP) and FeNO in the same model. There was no significant 
interaction by seroatopy. The BBzP metabolite association was significantly stronger among 
children who wheeze (p=0.04). 
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Discussion: Results suggest independent associations between exposures to DEP and BBzP and 
FeNO in a cohort of inner-city children. These two ubiquitous phthalates, likely to have large 




Phthalates are a group of high-production volume compounds added to plastics to confer 
flexibility, and used in personal care and other consumer products, as well as in home materials 
such as vinyl flooring (Schettler 2006). Several phthalates are endocrine disrupting compounds in 
animal models (Howdeshell et al. 2008), and human epidemiologic studies have associated early 
life exposure to several phthalates with childhood eczema and asthma, as well as adverse 
neurobehavioral and reproductive effects (Bornehag and Nanberg 2010; Swan 2008; Swan et al. 
2009; Whyatt et al. 2011). Numerous biomonitoring studies, including the U.S. National Health 
and Nutrition Examination Survey (NHANES), have monitored phthalate metabolites in urine and 
shown widespread exposure to many phthalates, including among children and inner-city 
populations (Adibi et al. 2008; CDC 2010; Kato et al. 2005; Silva et al. 2004; Teitelbaum et al. 
2008). Although phthalates are rapidly metabolized, the ubiquity of these metabolites in urine 
suggests that exposure occurs nearly constantly with contributions from ingestion, inhalation, and 
dermal absorption (Frederiksen et al. 2007). Personal air concentrations of two phthalates, diethyl 
phthalate (DEP), which is more volatile than most other phthalates, and butylbenzyl phthalate 
(BBzP), which is also found on respirable particles, were correlated with maternal urinary 
metabolite concentrations (rho = 0.27 and rho = 0.48) (Adibi et al. 2008). Thus inhalation is one 
potentially important route of exposure for these two phthalates with dietary exposure more 
important for several other phthalates, including di-n-butyl phthalate (DnBP) and di(2-ethylhexyl) 
phthalate (DEHP) (Wormuth et al. 2006). Children have higher urinary concentrations than adults 
to many of the phthalate metabolites (CDC 2010; Silva et al. 2004; Wormuth et al. 2006), 
indicating the need for additional study of the potential health consequences of these exposures. 
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Fractional exhaled nitric oxide (FeNO) is a non-invasive biomarker of airway inflammation 
that is associated with eosinophilic inflammation (Dweik et al. 2011). FeNO is an important 
marker of subclinical airway inflammation predictive of future respiratory health among asthmatic 
and non-asthmatics. Prospective epidemiologic studies have associated higher FeNO with an 
increased risk of new-onset asthma in children and new-onset wheeze in adults (Bastain et al. 
2011; Olin et al. 2010). FeNO also predicts exacerbations in asymptomatic asthmatic children after 
withdrawal of inhaled corticosteroids (Pijnenburg et al. 2005). Corticosteroid therapy but not 
bronchodilator usage reduces FeNO among children with acute asthma (Baraldi et al. 1997; Byrnes 
et al. 1997). FeNO is also responsive to environmental pollutants that contribute to respiratory 
health problems. Exposure to local air pollutants such as respirable particulate matter (PM2.5) and 
black carbon have been associated positively with FeNO as has formaldehyde in the home (Cornell 
et al. accepted 2011; Delfino et al. 2006; Franklin et al. 2000; McCreanor et al. 2007).  
In a cross-sectional case-control analysis of Swedish children ages 3-8, those with 
physician-confirmed asthma had higher bedroom dust concentrations of DEHP while higher 
bedroom dust concentrations of BBzP were found among those with physician confirmed rhinitis 
and eczema, allergic diseases that may be related to an asthmatic phenotype (Bornehag et al. 2004). 
In a cross-sectional analysis of n=240 adult NHANES participants with concurrent phthalate 
metabolite and lung function measures collected 1988-1994, urinary concentrations of the sum of 
mono-n-butyl phthalate (MnBP), a metabolite of DnBP, and mono-isobutyl phthalate, a metabolite 
of di-isobutyl phthalate, were associated with decreases in forced expiratory volume in 1 sec 
(FEV1), forced vital capacity (FVC), and peak expiratory flow (PEF), but only among males 
(n=100). Monoethyl phthalate (MEP), the metabolite of DEP, was also associated with decreases 
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in FEV1 and FVC only among males, and both estimates were for decreases of greater than 100 ml 
per interquartile range change in the log-adjusted metabolite concentration (Hoppin et al. 2004).  
Based on these prior human observational studies, we hypothesized that higher urinary 
concentrations of four phthalate metabolites: MEP, MnBP, monobenzyl phthalate (MBzP; the 
metabolite of BBzP), and mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP; a metabolite of 
DEHP) would be associated with higher concurrent FeNO in children. We also hypothesized that 
children with seroatopy and wheeze, as surrogate measures of allergy and the hyperresponsive 




Participants were selected based on available samples (requirements for adequate samples 
are discussed below) from the children in the Columbia Center for Children’s Environmental 
Health (CCCEH) study, a longitudinal birth cohort that enrolled n=727 pregnant nonsmoking 
Dominican and African American women free of hypertension, diabetes, and known HIV living in 
Northern Manhattan and the South Bronx between 1998-2006 (Perera et al. 2003). Informed 
consent approved by the institutional review board of Columbia University and the Centers for 
Disease Control and Prevention was obtained from all participants. Children in the current analysis 
(ages 4.9-9.5 years) provided a spot urine sample collected by research staff during a home or 
office visit within 7 days of an FeNO measure that was collected in a clinic or office setting. Of the 
280 children enrolled who provided at least one measure for both phthalates and FeNO, 89 had two 
measures, and two children had three, resulting in a total of n=373 paired observations of phthalate 
metabolites and FeNO. 
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Urinary phthalate metabolites were measured at the Centers for Disease Control and 
Prevention as previously described (Adibi et al. 2008; Kato et al. 2005). DEHP has several highly 
correlated metabolites in urine so we used the concentration of MEHHP as our proxy for exposure 
to DEHP because it has a longer half-life, higher average concentrations, and higher detection 
frequency than the monoester metabolite mono(2-ethylhexyl) phthalate (MEHP) (Preau et al. 
2010). In this dataset, those two metabolites had a rank correlation of 0.85 (p<0.001, n=373).  
Following guidelines from the American Thoracic Society (American Thoracic Society and 
European Respiratory Society 2005), FeNO was collected with a modified offline device (#CBSK 
01400, GE Instruments, Boulder, CO) appropriate for collection of FeNO from children as briefly 
summarized in the appendix and described previously (Perzanowski et al. 2008; Perzanowski et al. 
2010; Rosa et al. 2011). A gas syringe was used to collect samples of ambient nitric oxide (NO) at 
the time of collection. FeNO concentrations were quantified via chemiluminescence. FeNO data 
were excluded if the child had a cold at the time of the visit, did not inhale through the ambient NO 
scrubber, or if the room of the test had over 100 ppb ambient NO. 
Seroatopy was defined as specific IgE to dust mite, cockroach, or mouse allergens (≥0.35 
IU/ml) by ImmunoCap (Phadia, Uppsala, Sweden), in the closest serum sample collected within 
one year of the FeNO measure (Donohue et al. 2008). This measure was available for 86% of 
observations (n=322/373) from 248 children. Because phlebotomy often coincided with the 
collection of other specimens and data, a sensitivity analysis was performed restricting to n=167 
observations with seroatopy and FeNO measured in samples collected on the same day. 
As a proxy measure for children who might have airway hyperresponsiveness, mothers 
were asked whether their child had wheezing or whistling in the chest in the past 12 months at age 
5, 6, 7 and 9 years using the wheeze module of the validated International Study of Allergy and 
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Asthma in Children (ISAAC) questionnaire (Asher et al. 1995). A questionnaire was available 
from the day of the FeNO or the following 12 months for n=331 observations and a sensitivity 
analysis restricted the interaction analysis to the n=211 observations with wheeze questionnaires 
administered on the day of the FeNO measure. Because reports on single questionnaires may not 
characterize the episodic and variable timing of wheeze in childhood, we also used a larger set of 
repeated questionnaires to model the probability of wheezing in the last three months as a 
continuous measure at each FeNO collection for all n=373 observations. This probability was 
computed by multiplying each child’s probability of belonging to four latent patterns (classes) of 
childhood wheeze by the probability of wheezing in the past three months at the age of collection 
for each pattern. Individual posterior probabilities of class membership and wheeze prediction 
equations were derived from a four-class latent class growth analysis (LCGA). This LCGA 
included 7048 questionnaires on report of wheeze in the past 3 months from 15 timepoints between 
3 months and 9 years of age in a larger subset (n=689) of the children in the CCCEH study (Chen 
et al.).  
 
Statistical analysis 
Because individual children had one to three observations with phthalate and FeNO 
collections, repeated measures were modeled using generalized estimating equations (GEE), and 
confidence intervals and p-values associated with the regression coefficients were based on robust 
standard errors. All regression models included specific gravity as a covariate to adjust for urinary 
dilution (Barr et al. 2005), as well as a set of a priori potential confounders: age, sex, ethnicity, and 
ambient NO concentration. Concentrations of phthalate urinary metabolites, FeNO, and ambient 
NO were log transformed prior to analysis due to the right skew and high variance at the upper 
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range of their distributions. Regression parameter estimates are presented as percent differences in 
FeNO for a one log-unit higher urinary metabolite concentration. Analyses were conducted using 
R version 2.13.1 with the gee and ggplot2 packages for regression models and data visualization 
(Carey 2011; R Development Core Team 2011; Wickham 2009). 
 
Results 
The 280 participants included 144 girls and 136 boys, and were 66% Dominican and 34% 
African American. At the FeNO measure, 25% had a report of a smoker in the home, and 
participant ages ranged between ages 4.9 and 9.5 years (mean age 6.6, SD 1.6 years). Those 
included in the analysis did not differ from the remainder of the original cohort on major 
demographic factors collected at enrollment (see table E1 in Appendix). Exposures to the 
phthalates examined were widespread as suggested by the detection of the metabolites of all four 
phthalates in 100% of samples (n=373). Concentrations varied widely and the highest metabolite 
concentrations were for MEP as shown in Table 1. The concentrations of the four phthalate 
metabolites within each sample were positively correlated with a range of pair-wise Spearman’s 
correlations from rho = 0.23 (MEP and MBzP) to rho = 0.69 (MnBP and MBzP). 
 
Table 1. Distributional summary for unadjusted urinary metabolite concentrations (ng/ml) 
measured in 373 spot samples from 280 New York City children 4.9 to 9.5 years old. 
Metabolite n >LOD Min 25% 50% 75% 95% Max GM (95%CI) 
MEP 373 100% 11 83 169 347 1920 12100 182 (162 to 206) 
MnBP 373 100% 3 24 48 85 212 539 44 (40 to 49) 
MBzP 373 100% 1 15 32 70 354 2080 34 (30 to 39) 
MEHHP 373 100% 2 20 46 87 385 1690 46 (41 to 52) 
 
To characterize predictors of children’s urinary phthalate metabolite concentrations, GEE 
models with age, sex, and race/ethnicity as predictors were fit for each of the four log-transformed 
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metabolite concentrations also including specific gravity in the models as a covariate. The urinary 
concentrations of three of the metabolites were higher in females than in males: MEP (42% higher, 
95% CI, 12% to 80%, p=0.004), MnBP (28% higher, 95% CI 7% to 53%, p=0.007), and MEHHP 
(34% higher, 95% CI 9% to 65%, p=0.005). Only the urinary concentration of MEHHP varied 
with age (increasing 10% per year, 95% CI 2% to 18%, p=0.02). There was no significant 
difference by race/ethnicity for the urinary concentrations of any of the metabolites. 
 
Phthalate urinary metabolites and FeNO 
FeNO measures ranged from 2.3 to 71.6 ppb with a median of 7.9 ppb and an interquartile 
range from 5.7 to 12.4 ppb and were consistent with a log-normal distribution. In a GEE model of 
FeNO with age, sex, race/ethnicity, and ambient NO concentration as predictors, both age and 
ambient NO concentration were positively associated with FeNO. In four separate adjusted 
models, FeNO was associated with urinary concentrations of MEP, MnBP, and MBzP but not 
MEHHP, after controlling for specific gravity, age, sex, race/ethnicity, and ambient NO 
concentration (Table 2). The effect size for MnBP was slightly larger than for MEP and MBzP 
although all three were very similar and were consistent with linearity in adjusted models using 
quintiles of urinary concentration (Figure 1). For example, there was a 7.6% increase in FeNO 
(95% CI 2.2% to 13.3%, p=0.005) for each log-unit increase in MBzP concentrations, that would 
correspond to an FeNO concentration of 9.1 versus 8.1 ppb for a child at the 75th versus the 25th 
percentile of MBzP concentrations, assuming mean levels of covariates. Similarly, a log-unit 
increase in MEP concentration was associated with a 7.0% increase in FeNO (95% CI 1.6% to 
12.6%, p=0.008) adjusted for covariates, while a log unit change in MnBP concentration was 
associated with a 9.9% increase in FeNO (95% CI 1.8% to 18.8%, p=0.014) adjusting for 
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covariates. There was no significant interaction by child sex, and adjusting for having a smoker in 
the home did not change the magnitude or significance of estimates (data not shown). A simulation 
study was also used to explore the magnitude of confounding necessary to see the observed 
association (see Appendix). In a sensitivity analysis restricted to the subset of FeNO and urine 
samples from the same day (84% of observations, n=313), the estimates for MEP, MnBP, and 
MBzP were largely unchanged (beta estimates were 94%, 87%, and 90% of the beta estimates 
from the full dataset) and remained statistically significant, see Table E1 in the appendix.  
 
Table 2. Adjusteda percent difference in fractional concentration of nitric oxide for a one log-unit 
higher urinary phthalate metabolite concentration from GEE regression models 
 Single metabolites, four separate models 
(n=373) 
Metabolite % Difference (95% CI) p-value 
MEP 7.0 (1.6, 12.6) 0.01 
MnBP 9.9 (1.8, 18.7) 0.01 
MBzP 7.6 (2.2, 13.3) 0.005 
MEHHP 4.2 (-1.5, 10.3) 0.15 
    
 Single metabolites, separate models adjusted for seroatopy (n=322) 
Metabolite % Difference (95% CI) p-value 
MEP 6.7 (1.2, 12.5) 0.02 
MnBP 9.3 (1.0, 18.2) 0.02 
MBzP 8.4 (2.8, 14.3) 0.002 
MEHHP 3.5 (-2.7, 10.1) 0.26 
    
 All four metabolites in one model adjusted for seroatopy (n=322) 
Metabolite % Difference (95% CI) p-value 
MEP 6.1 (0.2, 12.4) 0.04 
MnBP -1.2 (-10.7, 9.4) 0.81 
MBzP 8.2 (1.7, 15.1) 0.01 
MEHHP 1.6 (-4.5, 8.1) 0.62 




Figure 1: The association between urinary concentrations of three phthalate metabolites: 
MEP, MnBP, and MBzP and FeNO from separate models (n=373 observations from 280 
children). 
Adjusted estimates for each quintile are shown as horizontal segments. The continuous linear 
association is shown as a wider grey line. Both quintile and continuous model estimates are 
adjusted and shown at mean levels of specific gravity, age, sex, race/ethnicity, and ambient NO. 
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Using measures within one year, 32% were classified as seroatopic at their FeNO 
observation (n=104/322). Adjusting for seroatopy did not substantially alter the estimates for the 
individual phthalate metabolites (Table 2). In sensitivity analyses similar results were seen when 
restricting to seroatopy measured on the day of FeNO collection (n=167), see Table E1 in the 
Appendix.  
In an adjusted multi-pollutant model of FeNO including concentrations of all four 
metabolites (MEP, MnBP, MBzP, and MEHHP) that was also adjusted for seroatopy, urinary 
concentrations of both MEP and MBzP remained statistically significant independent predictors of 
FeNO with similar effect size estimates to those in the single metabolite models as shown in Table 
2. While MEHHP concentrations remained non-significant as in the single metabolite models, the 
single-metabolite beta estimate for MnBP decreased from 0.089 in the seroatopy adjusted model to 
a beta of -0.012 in the multi-pollutant model and was no longer statistically significantly associated 
with FeNO after adjusting for the other phthalate metabolite concentrations (p=0.81). Therefore, 
the MnBP association with FeNO seen in the single phthalate model may be due to the high 
correlation between MnBP and MBzP. In the adjusted four-pollutant model, a log-unit higher 
concentration of MEP and MBzP was associated with a 6.1% increase (95% CI 0.2% to 12.4%, 
p=0.04) and a 8.2% increase (95% CI 1.7% to 15.1%, p=0.01) in FeNO respectively after adjusting 
for all four metabolite concentrations, seroatopy, specific gravity, age, sex, race/ethnicity, and 
ambient NO.  
 
Interaction between phthalate metabolites and seroatopy or wheeze  
There was no direct association between the urinary concentrations of any of the four 
metabolites with incident seroatopy or reported wheeze (see Appendix). 
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As seen in Figure 2, FeNO was higher among those with seroatopy (geometric mean (GM) 
11.6 ppb, n=104) than those without seroatopy (GM 7.4 ppb, n=218; p<0.001). Interaction terms 
found no significant difference in the slopes of the MEP or MBzP and FeNO associations between 





Figure 2: The association between MEP or MBzP urinary concentrations and FeNO 
stratified by seroatopy of the child (n=218 and n=104 observations from 248 children).  
Boxplots show the distribution of FeNO concentrations is higher among atopics than non-atopics 
(p<0.001). The interaction terms testing for a difference in slopes were not statistically significant 
(p=0.30 and p=0.43), shown at the mean specific gravity, age, sex, race/ethnicity, and ambient NO 
concentration. Main effects for both metabolites remained statistically significant after adjusting 




We also assessed the interaction between phthalate concentrations and wheeze using data 
from the ISAAC questionnaire responses to test whether children who wheeze are more 
susceptible to airway inflammation associated with phthalate exposure. Overall, 22% of children 
had a report of wheezing or whistling in the chest in the past 12 months at their FeNO observation 
or their next questionnaire collected within 12 months. There was no significant interaction 
between concentrations of MEP, MnBP, or MEHHP and report of wheeze in the past year in the 
association with FeNO. There was a significant positive interaction of the MBzP and FeNO 
association by ISAAC wheeze (Figure 3; p=0.038, n=331). In sensitivity analyses, this interaction 
was stronger and remained significant when restricted to ISAAC wheeze questionnaires asked on 
the same day as FeNO collection (p=0.009, n=211).  
 
Figure 3: The association between MBzP urinary concentrations and FeNO varies by 
whether the mother reported on the next questionnaire that the child had wheezing or 
whistling in the chest in the past 12 months (n=331 observations from 263 children).  
The interaction term between MBzP and the report of wheeze was positive and significant 
(p=0.038) in the adjusted model shown at the mean levels of specific gravity, age, sex, 




As a further exploration of the interaction between phthalates and wheeze, a latent class 
growth analysis was used to model the probability of wheezing in the past three months. This 
continuous variable was available for all n=373 observations and probabilities ranged from 0.01 to 
0.68 although they were highly skewed with a median of 0.04, a 75th percentile of 0.08, and a 95th 
percentile of 0.37. There was no evidence of interaction between concentrations of MEP, MnBP, 
or MEHHP and LCGA predicted probability of wheeze on FeNO. However, as in the analysis 
using a dichotomous ISAAC wheeze question, the interaction between urinary MBzP 
concentrations and the LCGA probability of wheezing on FeNO was positive and highly 
significant (p=0.004). The association between concentrations of MBzP and FeNO was of a larger 
magnitude among those with a higher probability of wheezing (Figure 4). 
 
Figure 4: The association between MBzP urinary concentrations and FeNO is stronger 
among children predicted to wheeze (n=373 observations from 280 children).  
The area of points is proportional to the probability of wheezing predicted from a latent class 
growth analysis (continuous variable ranging from 0.01 to 0.68). The three lines display the MBzP 
and FeNO association for participants at the median, 75th percentile, and the 95th percentile of the 
probability of wheeze shown at the mean specific gravity, age, sex, race/ethnicity, and ambient NO 
concentration from a multivariable GEE model. The interaction term between MBzP and the 





In this cross-sectional study, urinary concentrations of three phthalate metabolites (MEP, 
MnBP, and MBzP) were associated positively with FeNO in separate adjusted models. All three 
associations remained largely unchanged after adjusting for seroatopy. When all four metabolites 
(MEP, MnBP, MBzP, MEHHP) were put in the same adjusted model, MEP and MBzP remained 
independent predictors of higher FeNO, while concentrations of MnBP, which is highly correlated 
with MBzP, were no longer associated with FeNO. These results indicate that urinary biomarkers 
of exposure to two phthalates are associated with a measure of subclinical airway inflammation in 
children. 
Seroatopy is an important predictor of FeNO (Rosa et al. 2011), and allergen exposure can 
explain one-third of the FeNO variability among atopics (Sordillo et al. 2011). There were no 
statistically significant interactions to indicate that the association between individual metabolite 
concentrations and FeNO varied by seroatopy, although our sample size may have limited our 
ability to detect interactions.  
We hypothesized that asthmatic children with hyperresponsive airways, operationally 
defined based on report of wheeze, might be more susceptible to airway inflammation triggered by 
environmental exposures. Although this operational definition did not measure actual airway 
hyperresponsiveness and relied on subjective reports, we saw a positive interaction between MBzP 
urinary concentrations and wheeze when we dichotomously classified children based on the 
ISAAC question on wheeze in the past 12 months. There was also a positive interaction between 
urinary concentrations of MBzP and the probability of wheezing predicted from a latent class 
growth analysis of questionnaire data, indicating that the MBzP and FeNO association is stronger 
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among a subset of children who wheeze. Although wheeze itself is episodic, the LCGA-based 
prediction was based on the pattern of wheezing at up to 15 time points between 3 months and 9 
years of age and may offer a more stable indication of children with respiratory health concerns 
than a single questionnaire response. An additional advantage of the LCGA-based wheeze 
prediction is that it could be computed for all observations and derived a continuous variable using 
a large number of questionnaires and therefore may also be more informative than a dichotomous 
classification. Direct comparison of our two wheezing measures is difficult however, because the 
LCGA derived probability of wheeze over 3 months was based on a different question than the 
ISAAC wheeze and we did not propagate uncertainty estimates from the original LCGA model 
into the LCGA-based probability of wheeze. 
While the strength of the cross-sectional design is that it allows for the observation of 
effects that may be short-lived in response to exposures that vary over time, there are several 
important limitations. In an observational study, urinary concentrations of particular phthalate 
metabolites may also indicate exposure to other chemicals that share sources or chemical 
properties with the parent phthalates. For example, the mothers of the children in this analysis who 
reported the use of perfume or an index of uses of other personal care products during pregnancy 
had higher urinary concentrations of MEP than other pregnant women within the same cohort (Just 
et al. 2010), and can be expected to also have had higher exposure to other chemicals in those 
products, such as artificial fragrances as seen in sampling of indoor air (Rudel et al. 2010). The 
substantially higher urinary concentrations of MEP in girls than boys warrants further investigation 
as the burden of asthma and respiratory disease differentially increases for girls in adolescence, 
when exposure to DEP might be expected to remain high (Almqvist et al. 2008). Further, with 
phthalates, exposures occur to mixtures of correlated compounds. For example, in this study MnBP 
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and MBzP were highly correlated (rho = 0.69), which may be due to shared sources of exposure 
and the fact that MnBP is a minor product of BBzP (6%) (Anderson et al. 2001). MBzP has been 
shown previously to be a more reproducible biomarker than MnBP in spot urine samples collected 
over six months from children in New York City (Teitelbaum et al. 2008), its concentration may 
serve as a better marker of the mixture of related compounds than does the concentration of MnBP.  
Urinary concentrations of MBzP have recently been shown to be associated with a non-
specific marker of systemic inflammation in a large population-based analysis. MBzP 
concentrations were associated with increased serum C-reactive protein (CRP) in a dose-dependent 
fashion among 8346 NHANES participants (Ferguson et al. 2011). An interquartile range higher 
urinary MBzP concentration was associated with an average of 6.0% (95% CI 1.7% to 10.8%) 
higher CRP, and this association held in analyses restricted to younger NHANES participants 6-12 
and 13-19 years old. However, the mechanism through which phthalates are associated with 
systemic or airway inflammation remains unclear. Some phthalate metabolites, especially MEHP 
and MBzP activate the ubiquitously expressed nuclear peroxisome proliferator-activated receptors 
(PPAR) α and γ (Hurst and Waxman 2003), which are ligand-activated transcription factors 
important in a variety of physiological processes including airway inflammation and airway 
remodeling. For example, it has been shown that the expression of PPARγ is higher in the 
bronchial submucosa, airway epithelium, and smooth muscle of asthmatics than controls and is 
associated with decrements in lung function (Benayoun et al. 2001).  
Although there is an established and growing literature on the association between FeNO 
and components of local air pollution such as PM2.5 and black carbon (Cornell et al. accepted 2011; 
Delfino et al. 2006), this observational study of children is the first reporting a positive association 
between biomarkers of exposure to phthalates and FeNO. These results contrast with those from 
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two small controlled chamber studies. In a study of 10 adult volunteers (5 asthmatics), there was no 
increase in post- versus pre-challenge FeNO, although there was an increase in respiratory 
symptoms, after 4 hours in an exposure chamber with 1 m2 of PVC flooring shown to be releasing 
a breakdown product of DEHP (Tuomainen et al. 2006). In 18 healthy adult females, a non-
significant increase in FeNO relative to pre-challenge was seen after 4.5 hr with 4 m2 PVC surface 
stated as containing DEHP and BBzP, although FeNO decreased in the reference condition 
resulting in a significant difference from the challenge (Kolarik et al. 2009).  
 
Conclusions 
We report cross-sectional associations between children’s urinary concentrations of three 
phthalate metabolites and FeNO, a marker of airway inflammation. Concentrations of both MEP 
and MBzP remained associated with FeNO in a four-pollutant model. The association of 
concentrations of MBzP and FeNO was significantly stronger among children with reported 
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Sample collection of FeNO 
The protocol for FeNO collection has been described previously (Perzanowski et al. 2008; 
Perzanowski et al. 2010). FeNO was collected in mylar bags after diverting to discard the first 
portion of the breath, approximately 1-3 seconds of exhalation of dead-space air, using an offline 
device (#CBSK 01400, GE Instruments, Boulder, CO). Children were coached through attempts to 
gather three valid maneuvers in which they exhaled at 83 ml/sec and had either inhaled through the 
NO scrubber or there was an ambient NO of less than 20 ppb in the testing room. Data analysis 
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Demographic characteristics and sensitivity analyses 
 
Table E1. Characteristics of mother-child pairs included and excluded from analysis 





Mother’s Age: Mean (IQR)c 25 (21, 29) 25 (21, 29) 0.74 
Mother’s Ethnicity (%)  0.83 
African American 34 35  
Dominican 66 65  
Mother completed high school, 
GED, or greater  (%)d 65 63 0.62 
Never Married (%)d 69 64 0.17 
Maternal Asthma (%)d 24 21 0.39 
Child’s Sex (% male) 49 48 0.96 
Child's Seroatopy (%)e    
at 60 months 24 27 0.51 
at 108 months 39 37 0.83 
Child’s Wheeze (%)f    
at 60 months 25 26 0.94 
at 108 months 22 31 0.12 
GED, General Educational Development; GM, geometric mean; IQR, interquartile range 
aMissing: Education (n=1), Never Married (n=1), Child's seroatopy at 60 months (n =32), 108 
months (n=157), Wheeze at 60 months (n=15), Wheeze at 108 months (n=95)  
bMissing: Education (n=13), Never Married (n=5), Child's seroatopy at 60 months (n=208), 108 
months (n=341), Wheeze at 60 months (n=220), Wheeze at 108 months (n=313)  
cAge at delivery; assessed with Wilcoxon rank sum test 
dData from the prenatal questionnaire 
eSeroatopy defined as ≥0.35 IU/ml specific IgE to cockroach, dust mite, or mouse 
fWheeze from ISAAC question on wheezing or whistling in the chest in the past 12 months 
 
 There were no significant differences between those included in the analysis (n=280) and the 
remainder of the original cohort (n=447) in univariate testing. Similarly, a multivariable logistic 
regression model built with prenatal variables (age, ethnicity, education, marital status, maternal 
asthma, child sex, n=710) found no significant difference between those included and excluded 
from analysis. The large rate of missing data in the measures of seroatopy and wheeze for excluded 




Table E2: Adjusteda percent difference in fractional concentration of nitric oxide for a one log-unit 
higher urinary phthalate metabolite concentration from sensitivity analyses of GEE regression 
models restricting to urine samples collected on the same day as FeNO or adjusted for a subset of 
seroatopy samples collected on the same day as FeNO. 
 Single metabolites measured same day, 
four separate models (n=313) 
Single metabolites, four separate 
models adjusted for same day 
seroatopy (n=167) 
Metabolite % Difference (95% CI) p-value 
% 
Difference (95% CI) p-value 
MEP 6.6 (1.0, 12.5) 0.02 8.3 (1.0, 16.0) 0.02 
MnBP 8.6 (0.1, 17.8) 0.04 10.3 (0.3, 21.3) 0.04 
MBzP 6.9 (1.1, 13.0) 0.02 6.9 (-0.5, 14.9) 0.06 
MEHHP 2.6 (-3.5, 9.1) 0.39 3.5 (-5.3, 13.2) 0.44 






Simulation of confounding 
As a simulation exercise, we also used fake data to explore how strong a confounder would 
be needed to see an association such as we have reported if our analyzed exposure were only 
associated with the outcome through a correlated confounder such as another chemical component 
of personal care products. We explored a range of correlations between the confounder and the 
analyzed exposure as well as several values of the assigned association between the confounder 
and the outcome. To create a simple simulation that was comparable with our dataset, we 
generated repeated draws of n=373 independent samples for the correlated exposure variables from 
a random bivariate normal distribution with prespecified population level means and variances to 
match those of MEP concentrations from children in our study. The correlation between the 
confounder and analyzed exposure was varied from r = 0.10 to 0.60. In a recent study collecting 
24-hour indoor air samples, the concentration of DEP had a Kendall’s tau correlation with other 
common semivolatile endocrine disrupting compounds in indoor air in the range of 0.25 to 0.45 
(Rudel et al. 2010). The strength of the association of the confounder with the outcome variable 
was set to be approximately equal to, two times, or four times the strength of the observed 
association from the single pollutant model in this study (beta = 0.07, 0.14, or 0.28). In generating 
the outcome variable, error was added such that the coefficient of determination for the association 
of the confounder and outcome was R2 = 0.15, a value that is typical of molecular epidemiologic 
associations (sensitivity analysis showed similar patterns at R2 = 0.30, data not shown). Univariate 
regression models were built using only the correlated exposure (rather than the confounder 
directly associated with the outcome), and the regression coefficients were stored and averaged 
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over 100 simulations for each of the 11 levels of the correlation and 3 levels of the confounder 
beta.  
As expected, results showed that the apparent effect size of the analyzed exposure in the 
presence of a confounder increased with larger correlations between these exposures and was 
higher with larger effect sizes for the confounder. Simulation results show that in order to see an 
effect size of the magnitude observed for MEP in our data, a confounder would need to have either 
twice the effect size and a correlation of at least r = 0.5 or else have four times the effect size with a 
correlation of at least r = 0.25.  
 
Figure E1: Simulation of observed effect sizes under varying degrees of correlation with a 
confounder of differing strengths 
 
This simulation, while simplified to consider only a single exposure and single confounder, 
demonstrates that a correlated exposure acting as an unobserved confounder would need a 
considerably larger true effect size to induce the observed association between MEP and FeNO if 




Analysis of postnatal urinary phthalates and incident seroatopy 
While exposure to phthalates is likely to occur at all ages, a cross-sectional analysis with 
seroatopy may be inappropriate as the onset of allergic sensitization to aeroallergens is largely non-
reversible and incidence is spread over the childhood period. However, repeated sampling of both 
urinary phthalate concentrations and seroatopy at various ages in this cohort makes possible an 
analysis of the association of childhood exposure with later incident seroatopy. This analysis can 
be done on a larger subset of children in the CCCEH study without restricting to those with 
measures of FeNO. 
 
Methods 
Urinary metabolite concentrations were measured in urine samples collected at age 3 and 5 
years at the CDC as previously described. Seroatopy at a particular age was defined as specific IgE 
(≥0.35 IU/ml) to dust mite, cockroach, or mouse in samples from age 2 or 3 years (combined), age 
5, or age 7. Incident seroatopy at age 5 or 7 years was defined as new cases of seroatopy among 
those who had one or more samples collected at previous ages and had no previous positive 
specific IgE results. Thus, a child developing seroatopy between age 3 and 5 would not be included 
in the susceptible population at age 7. Logistic regression models using generalized estimating 
equations modeled incident seroatopy at age 5 and 7 and phthalate metabolite urinary 
concentrations two years prior adjusting for specific gravity, sex, race/ethnicity, age at atopy 





There were 240 children with phthalates measured at age 3, no seroatopy at age 2 or 3, and 
a seroatopy measure at age 5, as well as 147 children with phthalate measured at age 5, no 
seroatopy in available samples from ages 2, 3, or 5, and a measure of seroatopy at age 7. Overall, 
there were 387 observations with these available data from 295 children. There were 41/240 (17%) 
and 24/147 (16%) new incident cases of seroatopy at age 5 and 7 years respectively. There was no 
association between any of the individual metabolites of interest and incident seroatopy in the 
following two years (Supplemental Materials Table E3). 
 
Supplemental Materials Table E3: Adjusted Odds Ratios for a log unit change in children’s 
phthalate metabolite concentrations at age 3 or 5 and incident seroatopy over the following 
two years. 
Metabolite OR 95% CI  p-value 
MEP 1.20 (0.96 to 1.53) 0.12 
MnBP 0.89 (0.63 to 1.24) 0.47 
MBzP 1.09 (0.89 to 1.34) 0.37 
MEHHP 1.13 (0.82 to 1.57) 0.45 
 
Discussion 
We have reported previously that there was no association between a maternal urinary 
concentration of MBzP and the development of seroatopy by age 5 years in this population (Just et 
al. Submitted. 2011). In this analysis we also did not see any association between phthalate 
metabolite concentrations measured at age 3 or age 5 and the development of seroatopy over the 




Phthalate metabolites and wheeze 
In both the subset with FeNO data and a larger group of children from the full CCCEH 
cohort with available data, there was no consistent association between individual phthalate 
metabolite concentrations for the four metabolites of interest and concurrent report of wheeze at 
age 5 or at age 7 (Supplemental Materials Table E3). Although MEHHP appeared positively 
associated with wheeze at age 7, this attenuated and was no longer significant in the larger dataset. 
 
Supplemental Materials Table E4: Adjusteda odds ratio estimates for report of wheeze in the past 
year on ISAAC questionnaires at age 5 and 7 for a log unit increase of urinary phthalate metabolite 
concentration from separate single metabolite models restricted to kids in the FeNO analysis and 
those with available data in the larger CCCEH dataset 
Age 5 ISAAC Wheeze (n=232)  Age 5 ISAAC Wheeze (n=348) 
Metabolite OR (95% CI) p-value  Metabolite OR (95% CI) p-value 
MEP 0.82 (0.62, 1.07) 0.14  MEP 0.91 (0.74, 1.12) 0.37 
MnBP 0.89 (0.63, 1.26) 0.50  MnBP 0.92 (0.71, 1.20) 0.54 
MBzP 0.92 (0.72, 1.18) 0.52  MBzP 1.00 (0.82, 1.21) 0.98 
MEHHP 1.06 (0.78, 1.45) 0.70  MEHHP 1.11 (0.85, 1.46) 0.42 
         
Age 7 ISAAC Wheeze (n=175)  Age 7 ISAAC Wheeze (n=289) 
Metabolite OR (95% CI) p-value  Metabolite OR (95% CI) p-value 
MEP 1.05 (0.77, 1.44) 0.75  MEP 1.09 (0.86, 1.37) 0.47 
MnBP 1.12 (0.71, 1.76) 0.61  MnBP 0.91 (0.67, 1.24) 0.55 
MBzP 1.11 (0.81, 1.51) 0.50  MBzP 1.07 (0.85, 1.33) 0.56 
MEHHP 1.37 (1.01, 1.87) 0.04  MEHHP 1.19 (0.91, 1.54) 0.19 
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Chapter 8: Conclusion and future directions 
Summary of major findings 
The studies in the previous five chapters were designed to address a single unifying 
hypothesis of this dissertation: Early life exposure to a mixture of phthalates will have 
associations with adverse allergic and respiratory health outcomes in children. 
The components of this hypothesis were addressed in three working hypotheses with specific aims 
that dealt with exposure, statistical methods, and associations with health outcomes: 
 
Hypothesis 1: 
We predict that the use of personal care products and flooring materials in the home 
environment contribute to patterns of prenatal and childhood phthalate exposure. Specifically, we 
hypothesize that the use of perfume and other personal care products is associated with higher 
exposure to DEP and DnBP and that the presence of vinyl flooring materials that may contain 
phthalates is associated with higher exposure to BBzP but not DEHP. 
Principle findings from Specific Aim 1: 
Consistent with our hypothesis, the use of perfume and an index of other personal care 
products was associated with higher urinary concentrations of MEP among pregnant women. 
Contrary to our hypothesis, there was no association between use of nail products and MnBP. The 
lack of correlation between personal air DEP and urinary MEP concentrations among perfume 
users suggests that DEP exposure subsequent to perfume use, which is often applied directly to 
skin, may have a substantial dermal component not sampled by personal air monitoring. The 
correlation of air and urinary concentrations among non-users of perfume indicates that inhalation 
is an important potential route for exposure from other sources of DEP. Consistent with our 
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hypothesis, homes with flooring categorized as “vinyl or linoleum” had higher concentrations of 
BBzP in their indoor air, although, contrary to our hypothesis, they did not have higher 
concentrations of indoor air DEHP. Further, children living in homes with “vinyl or linoleum” 
flooring had higher urinary concentrations of MBzP. As anticipated, we found no correlation 
between indoor air DEHP and urinary DEHP metabolite concentrations.  We did not see any 
association between flooring type and DEHP metabolite concentrations. Taken together, these two 
exposure studies establish that routine behaviors and residential materials may make a substantial 
contribution to exposure to DEP and BBzP in pregnant women and children. 
 
Hypothesis 2: 
We hypothesize that simple Bayesian regression models can estimate associations between 
multiple correlated phthalate biomarker measures and a continuous health outcome and that these 
estimates will better reflect actual mixtures and be more stable than estimates from single 
biomarker or full linear regression models.  
Principle findings from Specific Aim 2: 
We constructed two simple Bayesian regression models with resulting effect size estimates 
for individual phthalate metabolites that were more realistic than those from models that consider 
each metabolite separately. Further, they  were more stable with smaller variances than from a full 
regression model. The flexibility of a Bayesian model that groups similar predictors was 
particularly helpful as it may be inappropriate to assume similar parameter estimates for other 
covariates, including potential confounders. While no single metabolite predominated the 
association with reduced gestational age, the three most negative effect estimates were for mono(3-
carboxypropyl) phthalate, a metabolite of high molecular weight phthalates including di-n-octyl 
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phthalate and two DEHP metabolites, mono(2-ethylhexyl) phthalate and mono(2-ethyl-5-
hydroxyhexyl) phthalate. 
 
Hypothesis 3:  
We predict that higher prenatal exposure to butylbenzyl phthalate will increase risk of early 
childhood eczema and production of proallergic immunoglobulin E (IgE) antibodies by age five 
years. We also predict that exposure to the four phthalates will be associated with increased 
concurrent airway inflammation (FeNO) among cohort children. 
Principle findings from Specific Aim 3: 
We found that prenatal urinary concentrations of MBzP were associated with report of 
child eczema. Associations were strongest for eczema that was reported by child age 24 months. 
There was no association between prenatal MBzP concentrations and the development of 
seroatopy measured with total or specific IgE to indoor aeroallergens up to child age 60 months. 
Children’s concentrations of MEP and MBzP were both associated with higher FeNO measured 
within seven days of the urine sample collection in a model that also included MnBP, MEHHP, 
and potential confounders. These associations did not appear to vary by seroatopy. However, the 
association between MBzP and FeNO was significantly stronger among children with wheeze. 
 
Connections between findings and broader relevance 
In our reanalysis of the association of eight phthalate metabolites with reduced gestational 
age (Chapter 5), we recommend Bayesian models as an alternative to conventional statistical 
approaches. In modeling children’s urinary concentrations of MEP, MnBP, MBzP and MEHHP 
(Chapter 7), we report results from models fit to one metabolite at a time as well as a full model 
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with all four in as predictors. Consistent with our warnings from Chapter 5, we saw that the 
correlation of MnBP and MBzP resulted in the former having a significant effect that was 
completely null when all four metabolites were in the model. However, the impact of 
multicollinearity on estimate stability was much larger in the application of phthalate metabolites 
and reduced gestational age. Because the DEHP metabolites were associated with reduced 
gestational age, this subset of the most highly correlated metabolites needed to be considered 
carefully. However, in the absence of any association between MEHHP and FeNO, it was 
unnecessary in Chapter 7 to model additional DEHP metabolites that had rank correlations with 
MEHHP of ≥0.85. As a result, our full model of four metabolites and FeNO  in Chapter 7 did not 
exhibit the same instability as the full model with three DEHP metabolites and five other 
metabolites and gestational age in Chapter 5. Future work is needed to determine what degree of 
multicollinearity such full models can sustain before the resulting instability makes it necessary to 
utilize additional techniques, such as the Bayesian models in Chapter 5. 
We found that personal care product use among the mothers was associated with higher 
MEP concentrations and that higher urinary concentrations of MEP in the children were associated 
with higher FeNO, a marker of airway inflammation. Our results suggest that personal care product 
use may be a modifiable source of exposure to DEP. However, interpretation of the association 
with airway inflammation is difficult because DEP, the parent phthalate of MEP, may be a proxy 
in these studies for a mixture of other semi-volatile or volatile organic compounds used in personal 
care products or other fragranced consumer products (e.g. air fresheners) (Peters 2005; Rudel et al. 
2010; Steinemann 2009; Steinemann et al. 2011). While the association between volatile organic 
compounds and asthma or airway inflammation is complicated due to the large number of potential 
exposures, proxy measures have shown relevant associations (Mendell 2007; Nielsen et al. 2007). 
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For example, the children of women in the highest decile of reported use of chemical household 
products versus the lowest decile were more likely to wheeze persistently (OR 2.3, 95% CI 1.2 to 
4.4) in a large European cohort study (Sherriff et al. 2005). 
Two of our strongest and most consistent findings were related to urinary concentrations of 
MBzP, a biomarker that we have previously reported is the most reliable of the phthalate 
metabolites during pregnancy (Adibi et al. 2008). We found that prenatal urinary concentrations of 
MBzP were associated with early eczema, and that urinary concentrations in children were 
associated positively with airway inflammation. We also found that residential flooring materials 
were associated with exposure to BBzP, but not DEHP. In light of this finding on exposure, it is 
perhaps worthwhile reconsidering previous literature that has seen associations between vinyl 
flooring materials and asthma or bronchial obstruction (Bornehag et al. 2004; Jaakkola et al. 1999; 
Larsson et al. 2010; Mendell 2007; Oie et al. 1997). Although these associations have been 
presumed to be related to exposure to DEHP, our work in exposure as well as the associations with 
eczema and airway inflammation suggest that perhaps BBzP plays a key role in the exposure-
response relation attributed to vinyl home materials. 
  
Future directions 
The studies in this dissertation have utilized environmental and biological samples to 
characterize exposure to phthalates, analyze effects of mixtures, and assess the association between 
prenatal and early-life exposure to four phthalates and risk of child eczema and airway 
inflammation. Future research will bridge across these areas of exposure science, statistical 
methodology, and health outcomes to better understand the role of phthalates in pediatric allergy 




Identifying sources of phthalate exposure 
Exposure science plays an important role in source identification as well as exposure 
characterization for epidemiologic studies. In the previous chapters, questionnaires and visual 
inspection methods were used to gather information on potential sources of exposure and these 
were related to concentrations measured in environmental and biomonitoring samples. The 
methods used here appeared sensitive in classifying participants with the highest exposure, but 
lacked specificity because not all products identified as potentially containing phthalates likely did 
so. One recommendation to increase the specificity of characterizing exposed populations would 
be to use X-ray fluorescence (XRF) methods on materials in the home. XRF can detect chlorine 
and therefore differentiate polyvinyl chloride (PVC) materials, which often have phthalate 
plasticizers added to give them flexibility, from other types of plastic or non-plastic materials (e.g. 
linoleum). Cohort studies that conduct home visits could utilize portable XRF devices to improve 
upon visual inspection in the characterization of materials that may contain phthalates. This non-
destructive additional screening might increase the specificity of exposure characterization by 
identifying flooring likely to contain phthalates without misclassifying linoleum or other surfaces 
as vinyl and without requiring a costly direct measurement of the flooring for phthalates. A more 
accurate characterization of flooring materials as PVC versus non-PVC, if validated by 
environmental sampling of phthalates, might be a useful proxy for chronic exposure to BBzP for 
future epidemiologic studies, although this would be of limited utility for retrospective exposure 




Improving epidemiologic models with exposure information 
Controlled dosing studies have demonstrated that phthalates have urinary elimination half-
lives of just a few hours (Anderson et al. 2001; Anderson et al. 2011; Koch et al. 2004; Schmid and 
Schlatter 1985). In two studies dosing adults, the modest relative standard deviation for phthalate 
metabolite concentrations between individuals of 20%-40% suggests that differences in 
metabolism can only explain a small portion in the biomarker variability seen in population studies 
(Anderson et al. 2001; Anderson et al. 2011). Instead, the concentrations of phthalate metabolites 
reflect the variability in exposure that can occur over short periods of time. We utilized this 
variability in these studies by examining cross-sectional associations of urinary metabolite 
concentrations with exhaled nitric oxide, a marker of airway inflammation that also varies over 
short temporal spans. For epidemiologic studies of more stable outcomes, the variability of the 
urinary phthalate metabolites, even over a single day, may be a challenge to characterizing 
exposure over a longer etiologic period. However, time-varying predictors of exposure can be used 
to correct for some sources of variability. For example, in a study that measured urinary 
metabolites in every urine void from eight adults over one week, there was a marked daily 
periodicity of the concentration of MEP, particularly on weekdays, that likely follows from the use 
of personal care products in the morning (Preau et al. 2010). If only single spot urines were 
available, combining information on time of day of collection with the measured urinary 
concentration would help to adjust where participant concentrations were relative to an expected 
daily average and might produce a more appropriate ranking of the inter-individual differences in 
exposure. In the context of a reproducibility study, the inclusion of time-varying predictors of 
exposure (such as time of day for MEP or time since last meal for DEHP since diet is the dominant 
route of exposure) would be expected to increase the intraclass correlation coefficient. This is 
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because reducing the intra-individual variability would increase the proportion of total variance 
that is between-persons. 
Combining an understanding of exposure sources with data on biomarker variability may 
increase the reliability of biomarkers as dosimeters of average prenatal and postnatal exposure 
levels. Improving exposure characterization from biomarkers will be of particular use in 
epidemiologic studies of health outcomes with etiologic periods that span months to years such as 
asthma and allergy. Future studies that utilize methods for reducing measurement error such as 
two-stage models could reduce bias and increase power to detect associations between the 
unobservable average internal exposure to phthalates and health outcomes (Thomas et al. 1993). 
One way to implement these approaches would be to use substudies with more intensive sampling 
to construct a representative average exposure in a random subset of the participant population. 
These averages could be used as an outcome in models using single spot measures of urinary 
metabolite concentrations, specific gravity, time of collection, and information on major sources 
for each of the phthalates of interest. The parameters from these exposure models could be used to 
predict average exposure for the entire population which would then be used as a predictor in the 
second stage association with health outcomes. Structural approaches that do not directly estimate 
the latent parameter of internal or average exposure in the two-stage approach could also be 
implemented as a future direction but require more sophisticated statistical methods. 
 
Future studies of eczema and airway inflammation 
Future studies seeking to replicate the association seen here between early-life exposure to 
butylbenzyl phthalate and early childhood eczema should consider alternatives to maternal report 
of child’s eczema to increase the objectivity of the assessment. For example, the standardized 
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SCORing Atopic Dermatitis (SCORAD) index, designed as a tool for clinical assessment and 
validated for interrater reliability, combines clinical skin examinations on extent and intensity of 
eczema with more subjective severity reports from the patient. This widely used tool could be 
collected during early clinical assessments to increase the objectivity of assessments and would 
likely increase the generalizability of study results as well. 
We hypothesized that children who wheeze might have hyperresponsive airways and thus 
might be more susceptible to airway inflammation resulting from exposure to phthalates. We found 
that the association between MBzP and FeNO is stronger among children with report of wheeze 
than among children without wheeze in the past 12 months (Chapter 7). The interaction was even 
more significant when we used a prediction of wheeze resulting from the pattern of report of 
wheeze in the past three months on up to 15 questionnaires collected through childhood. However, 
this finding might be improved with a more refined operational definition of airway 
hyperresponsiveness. Rather than using report of wheeze on questionnaires, an operational 
definition for hyperresponsiveness could combine participant history with objective measures such 
as improvement in forced expiratory volume in one second (FEV1) after bronchodilator as a 
measure of reversible airway obstruction. Clinical practice guidelines suggests that FeNO may be a 
particular useful marker of inflammation (e.g. as a result of persistent allergen exposure) or control 
(e.g. subsequent to inhaled corticosteroid therapy) among patients with eosinophilic asthma 
(Dweik et al. 2011). Thus, a more rigorous test of the hypothesis that the inflammatory response to 
phthalates is heightened among the susceptible could examine phthalate urinary metabolites and 
eosinophil counts from induced sputum samples from asthmatic and non-asthmatic children.  
The combined results of specific aims 1 and 3 identified potentially modifiable sources of 
exposure to two of the phthalates, DEP and BBzP, which were subsequently associated with 
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airway inflammation in children. One potentially powerful study design to better understand these 
results would be to conduct exposure reduction interventions among children. Such a trial could 
use biomarker measures to confirm that exposures to these phthalates were reduced by the 
intervention (Rudel et al. 2011), and use measurements of FeNO before, during, and after the 
intervention to see if short-term exposure reductions led to concomitant changes in airway 
inflammation. Although evidence-based exposure reduction strategies have not been tested for 
these two phthalates, we would hypothesize based on our results that eliminating the use of 
fragranced products would substantially reduce exposure to DEP. Similarly, we would expect that 
relocating children to homes that do not contain vinyl flooring materials might lead to substantially 
lower exposure to BBzP. For example, epidemiologic studies could be timed so as to take 
advantage of changes in indoor environment that result from household moves, renovations, or 
changes in school location. Combining the results from these studies on exposure sources and 
epidemiologic associations for these phthalates indicates future areas for investigation in the 
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